



**DSPACE**

<https://dspace.org/>

## **Modeling the Effects of Vaccination and Incubation on Covid-19 Transmission Dynamics**

**PETER KIBII CHERUIYOT**

**2025-11**

UoK

<https://ir-library.kabianga.ac.ke/handle/123456789/1164>

**MODELING THE EFFECTS OF VACCINATION AND INCUBATION ON COVID-19  
TRANSMISSION DYNAMICS**

**PETER KIBII CHERUIYOT**

**A Thesis Submitted to the Board of Graduate Studies in Partial Fulfillment of the  
Requirements for the Conferment of a Master of Science Degree in Applied Mathematics  
of the University of Kabianga**

**UNIVERSITY OF KABIANGA**

**NOVEMBER, 2025**

## DECLARATION AND APPROVAL

### Declaration

I declare that this thesis is my original work and has not been presented for award or conferment of any diploma or degree in this or any other institution.

Signature.....

Date.....

PETER KIBII CHERUIYOT

Reg No: PGC/AM/001/20

### Approval

This thesis has been submitted with our approval as the University Supervisors.

Signature.....

Date.....

Dr. Wesley Kirui

Department of Mathematics and Actuarial Sciences

South Eastern Kenya University

Signature.....

Date.....

Dr. Reuben Langat

Department of Mathematics, Actuarial and Physical Sciences

University of Kabianga

Signature.....

Date.....

Dr. Benard Tonui

Department of Mathematics, Actuarial and Physical Sciences

University of Kabianga

## ABSTRACT

The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) is a strain of Coronavirus that causes Coronavirus Disease 2019 (COVID-19). The respiratory illness responsible for the COVID-19 pandemic began in December 2019 in Wuhan city, China. Mathematical modeling has enabled the epidemiologist to understand the dynamics of the disease, its impact and future predictions in order to provide the governments with the best policies and strategies to curb the spread of the virus. Deterministic susceptible-vaccinated-asymptomatic-infectious-recovered (SVAIR) model was formulated incorporated with time delay. The delay accounts for the time lapsed between exposure and infectious period. In this study delay differential equations (DDEs) were formulated for the purposes of determining the stability of both disease free equilibrium (DFE) and endemic equilibrium point (EEP). It was found that the model was stable at both Disease Free Equilibrium (DFE) and Endemic Equilibrium Point (EEP) and was attained whenever  $R_0 < 1$  and  $R_0 > 1$  respectively. Calculations based on secondary data from various works of literature and the WHO dashboard was used. The basic reproduction number ( $R_0$ ) was computed using the next generation matrix (NGM) approach. The sensitivity analysis was carried out, it was found out that for all model parameters under study, the signs of the sensitivity indices of  $R_0$  were all negative. This implied that the model parameters under consideration contributed to the decline in the spread of the COVID-19 infection. It was noted that the rate of progression from asymptomatic to infectious  $\delta_1$  was more sensitive than other model parameters since it contributed the most negative sensitivity index of -0.9265. Finally, numerical simulation was done using MATLAB for validation of the analytical results. Graphical representation shows that stability is achieved when  $\tau > 5$  days and that  $R_0 = 0.95$  at DFE. Furthermore at EEP it was noted that  $R_0 = 1.02$  hence stability was guaranteed.

## **COPYRIGHT**

No part of this thesis may be reproduced by any means in full or in part except for short extracts for research or private study, critical scholarly review with acknowledgement or with prior permission from the author or the Dean School of Graduate Studies, University of Kabianga.

©Peter Kibii Cheruiyot , 2025

## **DEDICATION**

I devote this thesis to my wife Monicah and children Kipchirchir, Sandra, Chebii and Chesang.

I thank you for your love and moral support.

## **ACKNOWLEDGEMENT**

I want to start by giving thanks to God for this amazing chance to attend the University of Kabianga. Secondly, my sincere gratitude and appreciation goes to my supervisors; Dr. Wesley Kirui, Dr. Reuben Langat and Dr. Benard Tonui for their endless support, guidance and encouragement throughout the period of research writing, may God bless you all as you continue helping other students. I also take this opportunity to thank the Department of Mathematics, Actuarial and Physical Sciences lecturers as a whole for their encouragement throughout. Finally, I am grateful to my friends and postgraduate colleagues for giving me their valuable time ranging from academic discussions to social interaction. To my family, thank you for your moral and financial support, God bless you.

## TABLE OF CONTENTS

|                                      |             |
|--------------------------------------|-------------|
| <b>DECLARATION AND APPROVAL</b>      | <b>ii</b>   |
| <b>ABSTRACT</b>                      | <b>iii</b>  |
| <b>COPYRIGHT</b>                     | <b>iv</b>   |
| <b>DEDICATION</b>                    | <b>v</b>    |
| <b>ACKNOWLEDGEMENT</b>               | <b>v</b>    |
| <b>LIST OF TABLES</b>                | <b>xi</b>   |
| <b>LIST OF FIGURES</b>               | <b>xii</b>  |
| <b>LIST OF ABBREVIATIONS</b>         | <b>xiii</b> |
| <b>LIST OF SYMBOLS</b>               | <b>xiv</b>  |
| <b>DEFINITIONS OF TERMS</b>          | <b>xiv</b>  |
| <b>CHAPTER ONE</b>                   | <b>1</b>    |
| <b>INTRODUCTION</b>                  | <b>1</b>    |
| 1.1 Overview . . . . .               | 1           |
| 1.2 Background information . . . . . | 1           |
| 1.3 Vaccines . . . . .               | 3           |
| 1.4 Mathematical Models . . . . .    | 4           |

|                             |                                               |           |
|-----------------------------|-----------------------------------------------|-----------|
| 1.4.1                       | Deterministic model . . . . .                 | 4         |
| 1.4.2                       | Stochastic model . . . . .                    | 4         |
| 1.5                         | Basic reproduction number $R_0$ . . . . .     | 5         |
| 1.6                         | Next-Generation Matrix (NGM) . . . . .        | 6         |
| 1.7                         | Delay Differential Equations (DDEs) . . . . . | 6         |
| 1.8                         | Statement of the Problem . . . . .            | 7         |
| 1.9                         | Objective of the study . . . . .              | 7         |
| 1.9.1                       | General objective . . . . .                   | 7         |
| 1.9.2                       | Specific Objectives . . . . .                 | 7         |
| 1.10                        | Justification of the study . . . . .          | 8         |
| 1.11                        | Significance of the study . . . . .           | 8         |
| <b>CHAPTER TWO</b>          |                                               | <b>9</b>  |
| <b>LITERATURE REVIEW</b>    |                                               | <b>9</b>  |
| 2.1                         | Introduction . . . . .                        | 9         |
| 2.2                         | Review of Related Literature . . . . .        | 9         |
| 2.2.1                       | Mathematical models . . . . .                 | 9         |
| 2.3                         | Identification of the Knowledge Gap . . . . . | 15        |
| <b>CHAPTER THREE</b>        |                                               | <b>16</b> |
| <b>RESEARCH METHODOLOGY</b> |                                               | <b>16</b> |
| 3.1                         | Introduction . . . . .                        | 16        |
| 3.2                         | SVAIR Model for COVID-19 . . . . .            | 16        |
| 3.3                         | Model Assumptions . . . . .                   | 17        |
| 3.4                         | Model Equations . . . . .                     | 19        |

|                                                                         |                                                                        |           |
|-------------------------------------------------------------------------|------------------------------------------------------------------------|-----------|
| 3.4.1                                                                   | Model Preliminary Analysis . . . . .                                   | 19        |
| 3.4.2                                                                   | Positivity and Boundedness of the model . . . . .                      | 19        |
| 3.5                                                                     | Computation of Basic Reproduction Number $R_0$ . . . . .               | 21        |
| 3.6                                                                     | Disease Free Equilibrium Point and its Stabilities . . . . .           | 23        |
| 3.6.1                                                                   | Local Stability of Disease Free Equilibrium . . . . .                  | 23        |
| 3.6.2                                                                   | Global stability analysis of disease free equilibrium points . . . . . | 25        |
| 3.7                                                                     | The Endemic Equilibrium Point . . . . .                                | 27        |
| 3.7.1                                                                   | Stability of endemic equilibrium point . . . . .                       | 27        |
| <b>CHAPTER FOUR</b>                                                     |                                                                        | <b>31</b> |
| <b>RESULTS AND DISCUSSION</b>                                           |                                                                        | <b>31</b> |
| 4.1                                                                     | Introduction . . . . .                                                 | 31        |
| 4.2                                                                     | Numerical Simulations and Discussions . . . . .                        | 31        |
| 4.3                                                                     | Analysis of Basic Reproduction Number at DFE and EEP . . . . .         | 37        |
| 4.4                                                                     | Sensitivity Analysis of Basic Reproduction Number $R_o$ . . . . .      | 40        |
| <b>CHAPTER FIVE</b>                                                     |                                                                        | <b>43</b> |
| <b>CONCLUSION, RECOMMENDATIONS AND SUGGESTIONS FOR FURTHER RESEARCH</b> |                                                                        | <b>43</b> |
| 5.1                                                                     | Introduction . . . . .                                                 | 43        |
| 5.2                                                                     | Conclusion . . . . .                                                   | 43        |
| 5.3                                                                     | Recommendations . . . . .                                              | 44        |
| 5.4                                                                     | Suggestions for further research . . . . .                             | 44        |
| <b>APPENDICES</b>                                                       |                                                                        | <b>50</b> |
| APPENDIX I : MATLAB Code: Dynamics of COVID-19 against time             |                                                                        | <b>50</b> |

|                                                                               |           |
|-------------------------------------------------------------------------------|-----------|
| APPENDIX II : MATLAB Code: : $R_0$ variations with different model parameters | <b>52</b> |
| APPENDIX III : Clearance to commence field work                               | <b>54</b> |
| APPENDIX V : NACOSTI Research Permit                                          | <b>57</b> |
| APPENDIX VI : Publication from the Thesis                                     | <b>60</b> |

## LIST OF TABLES

|           |                                                                                     |    |
|-----------|-------------------------------------------------------------------------------------|----|
| Table 4.1 | Table of parameters and values . . . . .                                            | 32 |
| Table 4.2 | Table of parameters, parameter description, values and sensitivity indices of $R_o$ | 41 |

## LIST OF FIGURES

|            |                                                                 |    |
|------------|-----------------------------------------------------------------|----|
| Figure 1.1 | Susceptible – Infectious – Recovered (SIR) . . . . .            | 5  |
| Figure 1.2 | Susceptible – Exposed – Infectious – Recovered (SEIR) . . . . . | 5  |
| Figure 3.1 | SVAIR Model Flow Diagram . . . . .                              | 17 |
| Figure 4.1 | A plot of Susceptible Population against time (days) . . . . .  | 33 |
| Figure 4.2 | A plot of Vaccinated population against time (days) . . . . .   | 34 |
| Figure 4.3 | A plot of Recovered against Time . . . . .                      | 35 |
| Figure 4.4 | A plot of Infectious against Time . . . . .                     | 36 |
| Figure 4.5 | $R_0$ against Death rate due to COVID-19 ( $\mu$ ) . . . . .    | 37 |
| Figure 4.6 | $R_0$ against Gamma ( $\gamma$ ) . . . . .                      | 38 |
| Figure 4.7 | $R_0$ against Delta ( $\delta$ ) . . . . .                      | 39 |
| Figure 4.8 | $R_0$ against Time delay ( $\tau$ ) . . . . .                   | 40 |

## **LIST OF ABBREVIATIONS**

|            |                                                        |
|------------|--------------------------------------------------------|
| COVID-19   | Coronavirus Disease 2019                               |
| DFE        | Disease Free Equilibrium                               |
| DDEs       | Delay Differential Equations                           |
| EEP        | Endemic Equilibrium Point                              |
| MATLAB     | Mathematics Laboratory                                 |
| NGM        | Next Generation Matrix                                 |
| ODEs       | Ordinary Differential Equations                        |
| PDEs       | Partial Differential Equations                         |
| SIR        | Susceptible Infected Recovered                         |
| SEIR       | Susceptible Exposed Infected Recovered                 |
| SVAIR      | Susceptible Vaccinated Asymptomatic Infected Recovered |
| SARS-COV-2 | Severe Acute Respiratory Syndrome Coronavirus 2        |
| WHO        | World Health Organization                              |

## LIST OF SYMBOLS

|                 |                                                                                   |
|-----------------|-----------------------------------------------------------------------------------|
| $\tau$          | Incubation period                                                                 |
| $\gamma$        | Natural death rate                                                                |
| $\alpha$        | Rate of recovery                                                                  |
| $S$             | Susceptible individuals                                                           |
| $V$             | Vaccinated individuals                                                            |
| $A$             | Asymptomatic individuals                                                          |
| $I$             | Infectious                                                                        |
| $R$             | Removed                                                                           |
| $N$             | Total population                                                                  |
| $R_0$           | Basic Reproduction Number                                                         |
| $\mu$           | Disease induced death rate                                                        |
| $P$             | Recruitment rate into susceptible                                                 |
| $\omega$        | Proportion of recruited individuals who are vaccinated                            |
| $\beta_1$       | Transition rate of susceptible individuals to infectious class per contact time.  |
| $\beta_2$       | Transition rate of susceptible individuals to asymptomatic class per contact time |
| $\delta_1$      | Transition rate of asymptomatic individuals into infectious class                 |
| $\delta_2$      | Recovery rate of asymptomatic individuals                                         |
| $\varepsilon_1$ | Transition rate of vaccinated individuals to infectious class per unit time       |
| $\varepsilon_2$ | Transition rate of vaccinated individuals to asymptomatic class per unit time     |
| $\varepsilon_3$ | Transition rate of vaccinated individuals to recovered class per unit time        |

## DEFINITIONS OF TERMS

**Basic reproduction number:** The mean number of new infections arising from a single infectious person introduced into a purely susceptible population, (Martcheva M et al., 2015.)

**Delay Differential Equation (DDEs) :** Are a type of differential equation in which the derivative of the unknown function at a given time is given in terms of the values of the function at previous time.

**Epidemiology:** This is a branch of medical science that studies the distribution of disease in human populations and the factors determining that distribution, chiefly by the use of statistics

**Infectious disease:** Infectious diseases are the diseases caused by various pathogenic microorganisms such as virus, bacteria, protozoan, fungi, and other parasites.

**Incubation period:** The period between exposure to an infectious agent and the onset of symptoms of the disease.

**Mathematical modeling:** The art of translating problems from the real life phenomena into tractable mathematical formulations whose theoretical and numerical analysis provides insights answers and guidance useful for any particular phenomenon, (McKendrick et al., 1997.)

**Prevalence:** The number of people who have the disease at a specific time.

## **CHAPTER ONE**

### **INTRODUCTION**

#### **1.1 Overview**

Background data on the kinetics of COVID-19 transmission is covered in this chapter. Additionally, the definition of delay differential equations is provided. This includes the next-generation matrix for calculating the basic reproduction number  $R_0$ , as well as the dynamic equations of an example SIR and SEIR model. Lastly, the statement of the problem, objectives of the study, justification of the study and significance of the study are considered.

#### **1.2 Background information**

The devastating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) is a strain of Coronavirus that causes Coronavirus Disease 2019 (COVID-19). The respiratory illness responsible for the COVID-19 pandemic which began in December 2019 (WHO, 2020) in Wuhan City, China and spread to many countries in the world (Shen et al., 2020). Kenya reported its first case of COVID-19 in March 2020. This resulted in the restriction of movement by the government. This included the closure of all learning institutions (McCloskey et al., 2020)

The COVID-19 pandemic has caused a public health and economic crisis worldwide. In response to the pandemic, countries implemented non-pharmaceutical interventions (NPIs), but social and economic consequences of certain NPIs made them unsustainable in the long-term. The rollout of COVID-19 vaccines following approval in December 2020 and in early 2021 contributed to a substantial reduction in pandemic burden, thus raising the possibility of relaxing NPIs. While emergence of more transmissible variants presented new challenges, many countries, such as Switzerland, were faced with having to make decisions on when and how to relax NPIs while

continuing to protect their population.

As vaccination coverage against SARS-CoV-2 increases amidst the emergence and spread of more infectious and potentially more deadly viral variants, decisions on timing and extent of relaxing effective, but unsustainable, non-pharmaceutical interventions (NPIs) need to be reviewed. Non-pharmaceutical interventions (NPIs) can curb the spread of SARS-CoV-2 in an otherwise unprotected population by reducing the number of potentially transmissible pairwise contacts. In Kenya, NPIs have targeted several aspects of public life, including closure of learning institutions, restaurants and other entertainment venues, restrictions in sizes of spontaneous gatherings, the cancellation of events and facemask mandates in publicly accessible spaces.

As of 18th April 2022, COVID-19 had spread to nearly every country in the world, resulting in 500,186,525 confirmed cases of infection and 6,190,349 deaths globally, according to the WHO's pandemic declaration from March 2020 (WHO, 2020). The number of COVID-19 cases reported to WHO by selected countries as at April 2022 include ; USA had 79,716,960 confirmed cases and 2,711,776 deaths, United Kingdom had reported 21,715,120 confirmed cases and 979,321 deaths, Africa had reported cumulative of 8,676,141 confirmed cases and 171,350 deaths and Kenya had reported 323,588 confirmed cases and 5649 deaths, (Shen et al., 2020).

Over time, it became evident that the Kenyan government's non-pharmaceutical mitigation measures to curb the spread of COVID-19 were not effective. Use of face masks, keeping of social distance, routine hand washing, isolation of suspected cases and contact tracing are a few examples of such intervention measures. Because of the rapid spread of COVID-19 globally, vaccination has been identified as the best containment strategy by several countries. The WHO approved COVID-19 vaccines, but these vaccines remain inadequate in supply and developing nations continue to experience the shortages of COVID-19 vaccines.

Kenya used different types of vaccines such as Astra Zeneca, Moderna, Pfizer and Johnson and Johnson. About 15% of the whole population had received further booster vaccinations totaling to about 285,700 individuals, one year after Kenya began administering vaccines on March 5, 2021. The public delayed uptake of the COVID-19 vaccine led to daily reports of COVID-19 cases to fluctuate, making it difficult to forecast how many COVID-19 cases may occur in the

future. The coronaviruses had a high risk of being transmitted from person to person (Wangari et al., 2021).

Some developed nations manufactured their own COVID-19 vaccines which became a greater challenge for developing nations to obtain enough vaccines to administer to their populations because of the growing demands for the manufactured vaccines (Prieto Curiel et al., 2021), this lowered the rate of vaccination. Less than 20% of the population in Kenya received a full vaccination, one and a half year after vaccination program began. The mathematical model would take these therapeutic approaches into account; including vaccination for those who are susceptible and treatment for those who are infectious.

### **1.3 Vaccines**

Fully susceptible, partially susceptible and actively infected individuals not in hospital can potentially receive a vaccine. Vaccination was modeled using two assumptions: first, to trigger an immune response that blocks transmission for a proportion of exposure events, and second, to reduce the probability of developing symptoms if infection does occur. Upon vaccination, there is a time delay until the full efficacy of the vaccine is realized. Kenya used different types of vaccines such as Astra Zeneca, Moderna, Pfizer and Johnson and Johnson in which in this study, the immune response for all vaccines was assumed to be equal. We assume the vaccine is 80% transmission blocking and has a further 75% probability of preventing symptoms leading to the observed 95% vaccine efficacy reported in clinical trials (Baden et al., 2021). In this study, we do not model decay of vaccine efficacy over time due to variants mutation.

The COVID-19 pandemic has caused a public health and economic crisis worldwide. In response to the pandemic, countries implemented non-pharmaceutical interventions (NPIs), but social and economic consequences of certain NPIs made them unsustainable in the long-term. The rollout of COVID-19 vaccines following approval in December 2020 and in early 2021 contributed to a substantial reduction in pandemic burden, thus raising the possibility of relaxing NPIs. While emergence of more transmissible variants presented new challenges, many countries, such as Kenya, were faced with having to make decisions on when and how to relax NPIs while continuing to protect their population. Mathematical models have proven to be useful in

providing insights to support this type of country-wide decision-making around different control strategies and public health objectives (Hall et al 2022). Here, we present a deterministic COVID-19 disease model which captures COVID-19 transmission dynamics using delay differential equations. The total population was subdivided into five compartments namely: Susceptible (S), Vaccinated (V), Asymptomatic (A), Infectious (I) and Recovered (R). In this study therefore, a SVAIR mathematical model for COVID-19 disease transmission dynamics was developed.

## **1.4 Mathematical Models**

Epidemiologists use mathematical models to describe the dynamics of infectious diseases. There are two types of mathematical models namely; deterministic and stochastic models.

A stochastic, deterministic, individual-based transmission model of SARS-CoV-2 infection and COVID-19 disease model are just a few examples of mathematical models among many. The COVID-19 disease model tracks the characteristics of individuals such as age, risk-group (namely those with comorbidity), SARS-CoV-2 infection status, COVID-19 disease state, level of immunity, and vaccination details. If infected, an individual's viral load is tracked as a function of the time since the infection, along with the viral variant with which an individual is infected. The model captures viral transmission as infectious and susceptible people come into contact with each other. The probability of transmission is dependent on the viral load of the infectious individual, the variant of the virus being transmitted, and any partial immunity acquired by the susceptible individual either through previous infection or vaccination (Baden et al., 2021)). Waning immunity was not considered in this study.


### **1.4.1 Deterministic model**

These models provide the actual prediction of future events without the use of probability. The deterministic occurrence contains all the information required to confidently predict the results.

### **1.4.2 Stochastic model**


A stochastic model randomly addresses the likelihood of an event happening. Deterministic and stochastic models have various compartments, they include; SI, SIR, SEIR, SEIRS among many

others by considering different compartments. The prediction of these models is determined entirely by their initial conditions set of underlying delay differential equations and input of parameter values. The following are some of the examples of deterministic models used in studying the dynamics of infectious diseases. Susceptible – Infectious – Recovered (SIR) models are models that considers that transmission of a disease moves from susceptible class to infectious class then to recovered class as shown in **Figure 1.1** below.



Susceptible – Infectious – Recovered (SIR)

On the other hand the Susceptible – Exposed – Infectious – Recovered (SEIR) models are models that consider that transfer of a disease moves from susceptible compartment to exposed compartment to infectious compartment to recovered compartment as shown in **Figure 1.2** below.



Susceptible – Exposed – Infectious – Recovered (SEIR)

In this study a deterministic model for COVID-19, which incorporate vaccination and time delay was formulated because when an individual is vaccinated or infected there is a latent period laps before herd immunity is attained or being infectious.

### 1.5 Basic reproduction number $R_0$

In epidemiology, the basic reproduction number of an infection is the mean number of new infections arising from a single infectious person introduced into a purely susceptible population during infectious period. The basic reproduction number  $R_0$  is the threshold for many epidemiological models. When  $R_0 > 1$  the disease-free equilibrium point is unstable, the infection

will be able to spread in a population and locally stable for  $R_0 < 1$ , the infection dies out in the long run. To obtain  $R_0$  the dominant eigenvalue of the next generation matrix (NGM) is considered,(Antonini et al., 2020)

## 1.6 Next-Generation Matrix (NGM)

In the mathematical model, the next generation matrix is used to calculate the fundamental reproductive number from the Jacobian matrix. The Jacobian matrix is derived from compartmental diagrams and is deduced from the first partial derivatives of sets of equations. By decomposing the Jacobian matrix for the infected sub-population into the transmission matrix and the transition matrix that describe compartment mobility and account for the number of new infections, the next-generation matrix can be used to calculate the basic reproductive number  $R_0$ . Throughout the computation of the NGM, the transmission and transition matrices are employed. The dominant eigenvalues obtained by picking the largest eigenvalue of the NGM is what gives the  $R_0$ , ( Diekmann et al., 2010).Between exposure and infectious there is time lapsed called incubation period in which the infected individual takes to become infectious and transmit the virus to others, this period is considered as time delay in mathematical modeling. The effects of time delay during quarantine and isolation period were not effectively considered and therefore time delay should be incorporated in COVID-19 models.

## 1.7 Delay Differential Equations (DDEs)

Delay differential equations (DDEs) are a type of differential equation in which the derivative of the unknown function at a certain time is given in terms of the values of the function at previous times. A general form of the time-delay differential equation for  $x(t) \in \mathbb{R}^n$  is

$$\frac{dy}{dx} = f(y(t)), y(t - \tau_1), y(t - \tau_2), \dots, y(t - \tau_n)) \quad (1.1)$$

Which is solved on  $a \leq t \leq b$  with given history and where;

$t$  is the time

$\tau$  is the time delay

a and b are values of t

f is a given function that may depend on the current time t, the current state y(t) and the delayed state y(t-τ)

There are two types of delay differential equations; Constant DDEs and Variable DDEs. In this study, constant DDEs were considered. This differential equation takes the form;

$$\frac{dx}{dt} = f(x(t), x(t - \tau), t) \quad (1.2)$$

Where  $x \in R^n$  and the quantity  $\tau$  is a positive constant and  $t$  is time , ( Thompson et al., 2007)

## **1.8 Statement of the Problem**

The main problem facing the health sector is prevention, treatment, the increased number of asymptomatic individuals and the time delays due to incubation period. This has increased the overall number of infected individuals and deaths that have been reported over time. The COVID-19 pandemic has been mostly controlled by vaccination (Starr et al., 2021). The effects of time delay on the COVID-19 transmission dynamics should be incorporated. Its worth to note that between the exposure and being infectious there is a time delay usually referred to as incubation period. In this study a Susceptible-Vaccinated-Asymptomatic-Infectious-Recovered (SVAIR) mathematical model that incorporates the effects of vaccination and incubation on COVID-19 transmission dynamics in Kenya is developed.

## **1.9 Objective of the study**

### **1.9.1 General objective**

To model the effects of vaccination and incubation on COVID-19 transmission dynamics using delay differential equations.

### **1.9.2 Specific Objectives**

- (i) To formulate a mathematical model that incorporate vaccination and incubation period on COVID-19 transmission dynamics

- (ii) To determine the equilibrium points of the SVAIR mathematical model developed and their stabilities.
- (iii) To perform sensitivity analysis of the SVAIR model to the parameters of the model.
- (iv) To carry out numerical simulation of the SVAIR model developed using MATLAB.

### **1.10 Justification of the study**

The deterministic SVAIR mathematical model developed in this study is important in addressing the transmission dynamics of COVID-19. The study took into consideration the effects of vaccination and time delay on the basic reproduction number. During the early spread of COVID-19, non-pharmaceutical measures were not effective, therefore vaccination was introduced as the best alternative measure to curb its spread but time delay was not considered in the previous mathematical models.

### **1.11 Significance of the study**

Infectious diseases like COVID-19 caused of sickness and death globally. This study is of great significance in the following areas: health sector and economy of the country. The model access the likely effects of the mitigation measures being applied and determine the expected epidemic trajectories if the vaccination program may not be fully implemented. Non-pharmaceutical measures such as face masking, keeping social distance, isolation and quarantine of suspected cases, have not been effective methods in curbing the spread of COVID 19. This model identify the immediate response on the best interventions that can be put in place to ensure normal operations even during the time of pandemic. The impact of COVID-19 pandemic on both global and local economy has been greatly felt. The model will inform the formulation of policies that will ease the impact of COVID-19 in the country.

## **CHAPTER TWO**

### **LITERATURE REVIEW**

#### **2.1 Introduction**

Many epidemiologists have sought to understand the dynamics of infectious diseases using mathematical models. In both developed and less developed countries, the COVID-19 pandemic has recently caused loss of lives. This chapter will provide an overview on the previous related studies which have been done by different scholars on COVID-19 dynamics. Finally this chapter also identify the knowledge gaps that exist on the previous studies and thus the need to carry out this study with an aim of bridging the existing gap.

#### **2.2 Review of Related Literature**

##### **2.2.1 Mathematical models**

Starting with the work of Daniel Bernoulli in 1760, the development of mathematical models has been critical in our understanding of the dynamics of infectious diseases. With the work of Kermack and McKendrick(1927), mathematical models have since been used to provide framework for understanding the dynamics of infectious diseases. COVID-19 being an infectious disease, its transmission dynamics models are flourishing and exist in many literature.

Early work on mathematical modeling was a study by Daniel Bernoulli on the deaths from smallpox that published in 1766. The use of mathematical models to model infectious disease gained traction in early 20th century beginning with Hamer's model on the recurrence of measles epidemic in 1906. This was followed by a study on the transmission dynamics of malaria between mosquitoes and humans, (Rose 1911). McKendrick et al., 1927 extended malaria model and studied the conditions for the spread of the disease and control mechanism.

Different types of epidemics that have since hit the World in the recent past include SARS-CoV in 2002-2003, Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012, Ebola in 1976 and 2013, H1N1 in 2009 and finally SARS-Cov-2 (COVID-19) in December 2019 (Alzubadi et al., 2023). Mathematical analysis of the spread and control of the novel coronavirus (COVID-19) in China informed the WHO (World Health Organization) of the outbreak. Later, on January 20, 2020, scientists from China's National Health Commission expressed its potential to spread from one human to another upon the confirmation of two cases in Guangdong upon visiting Wuhan. Later, the Wuhan authorities announced new measures for the control and prevention of this epidemic.

The novel coronavirus identified as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) is a strain of Coronavirus that causes Coronavirus Disease 2019. This disease was named by the World Health Organization (WHO) as Coronavirus Disease 2019 (COVID-19) (Sonani et al., 2020). WHO declared COVID-19 a pandemic in March 2020. Since March 2020, the pandemic in China has been substantially under control, yet, it continues to be a significant threat to global health and other sectors in the world. The effectiveness of China's healthcare system and awareness campaigns, helped the country to contained the COVID-19 pandemic and were one of the main factors contributing to its success in the fight against the disease, (Musa et al., 2022).

The most populated country in Africa, Nigeria, was affected by COVID-19 and other infectious and non-infectious diseases. Even in a normal circumstance, Nigeria healthcare system falls short of providing its people with the fundamental and necessary healthcare they required. As of January, 2020, the Nigeria Center for Disease Control (NCDC) had tallied 122,996 active cases and 1,507 fatalities at the time COVID-19 infection was not then treatable with vaccination or antiviral medication. As a result, a variety of non-pharmaceutical interventions including social isolation, face-masking, contact tracing, community-wide lock-downs, quarantining of suspected cases and the dissemination of health information about COVID-19 were used to control the spread of COVID-19 at that time.

Musa et al., (2022), investigated the infection fatality rate and infection rate of COVID-19

in Nigeria using a susceptible-exposed-infectious-recovered (SEIR) based model with a time-varying transmission rate controlled by systems of delayed differential equations (DDEs). They discovered that the awareness campaigns, in particular the use of non-pharmaceutical measures in mitigating the spread of COVID-19 were effective during the earliest period of infection. This study fails to incorporate effects of vaccination in transmission dynamics.

Jayaweera et al., (2020), in their studies of the mathematical modeling of COVID-19 with diffusion and control using systems of ordinary differential equations (ODEs), found out that it was important to understand the dynamics of the infection in the period of early spread. They also pointed out the effectiveness of control measures to established whether sustained transmission was likely to occur in new locations. The model was used to examine the COVID-19 spread in Wuhan, China from both inside and outside the city. The outbreak variations in Wuhan between January and February 2020 were computed. These computations were used to determine whether the disease carriers could be brought outside Wuhan city in China and could lead to a sustained human-to-human spread.

The SEIR model formulated used data on cases of COVID-19 in China and cases abroad that started in Wuhan city to assess how the disease transmission varied over time in January and February 2020. The probability that newly found cases could spark an outbreak in additional locations was computed. The mean daily basic reproduction number  $R_0$  for Wuhan was also computed (the expected number of secondary cases following the introduction of one infected individual into a fully susceptible population). According to the study, a disease must have  $R_0 > 1$  in order to spread among a host population because  $R_0$  has a threshold value of this magnitude. The basic reproduction rate dropped from 2.45 one week prior to the introduction of travel restrictions on January 23, 2020, to 1.05 one week thereafter.

As of August 2020, there were 19,187,943 confirmed cases of COVID-19 worldwide, including 716,075 fatalities, according to the report by (Sonani et al.,2020). In India, there were 2,088,611 confirmed cases and 42,518 fatalities; in the United States, there were 4,836,930 confirmed cases and 158,606 fatalities; in Spain, there were 314,362 confirmed cases and 28,503 fatalities and in South Africa, there were 545,476 confirmed cases and 9909 fatalities. The majority of

near-the-beginning holder's organisms were found in Wuhan, China in December 2019, while the majority of worldwide transmitted overseas holders were found to have traveled to and from Wuhan (Cohen et al., 2020).

A time delay dynamic model with a set of nonlinear DDEs were used to model and analyze COVID-19 transmission by (Cong Y et al., 2020). The study compared the global spread of the new coronary pneumonia epidemic at the beginning of 2020 to COVID-19 in order to mimic COVID-19 and assess the escalation of the epidemic in Beijing and Wuhan cities of China. They found out that during a short time, Wuhan city experienced a sharp rise in the number of infections. The analysis discovered that the pandemic was firmly under control and that the known cases had cleared up after several months of isolation and quarantine. After several months of reporting no new local cases, a new round of coronary pneumonia broke out in Beijing city on June 10, 2020. Several national and local governments ignored WHO recommendations but revived the economy and eased restrictions before the pandemic situation had been successfully controlled. Because the relationship between epidemic prevention and control and the reviving of the economy is difficult to balance, the model predicted high possibilities of future outbreak. It may be crucial to fully deliver antiviral medications and vaccines to Kenya's population in order to curb the spread of the pandemic and control it. In the absence of vaccines, early detection, isolation and treatment were then the most efficient intervention measures (Xu et al., 2021). The study only concentrated on non-pharmaceutical approaches for containing and lessening the pandemic impact in the absence of reliable vaccines or antivirals. These mitigation measures were temporary, since over time, the general populace has a tendency to loosen them, which would accelerate the spread of COVID-19. This study did not consider how the COVID-19 incubation period affected the isolated and confined patients.

Wangari et al., (2021), studied the mathematical modeling of COVID-19 transmission in Kenya, a model with a re-infection transmission mechanism. They found out that a large pool of infectious people who were asymptomatic would eventually increase symptomatic people with mild and severe symptoms, which may eventually increase the overall number of reported deaths. The study suggested that re-infection of recovered people who had lost their protective immunity caused this situation. The model uses deterministic ordinary differential equations (ODEs) for

computation of basic reproduction number.

Using face masks significantly lowered COVID-19 prevalence when compared to merely maintaining social distance, according to the model used to evaluate the efficacy of multiple non-pharmaceutical strategies for lowering COVID-19. Furthermore, it showed that the COVID-19 surge could be greatly decreased by raising the rate at which asymptomatic patients were discovered using contact tracing, testing and isolation. The peak COVID-19 infection was greatly delayed with only the use of face masks and keeping social distance. This has received substantial support from numerical simulations, which showed that COVID-19 transmission could be reduced more successfully when parameters that account for routine face masking and keeping social distance were combined.

Unfortunately, it's model did not take into account the incubation period during asymptomatic period. It did not state how asymptomatic cases would affect Kenya's low rate of vaccination program, including whether or not the program would successfully stop the spread of COVID-19. In addition, whether the people who received the booster shots would be fully protected. The study gives predictions about the possibility of disease burden, morbidity and death. It called for further research on the problems presented by asymptomatic patients in connection with reinfection.

Diagne et al., (2021), mathematically modeled the transmission mechanism of COVID-19. They featured the fundamental dynamics of the disease as well as two critical therapeutic approaches, that is, vaccination of those at risk and treatment of those already sick. On whether the effective reproduction number  $R_0$  is less than or greater than a unit, they found out that both the endemic equilibrium and the disease-free equilibrium were globally stable. The nonlinear system of equations utilized in this study to model the transmission dynamics of COVID-19 was developed using ordinary differential equations (ODEs).

The model was fitted using daily Senegal cumulative data at the start of the COVID-19 pandemic and a basic reproduction number  $R_0 = 1.31$ . The simulation outcomes demonstrated that further efforts such as non-pharmaceutical public health programs were to continue being applied when  $R_0 > 1$ , regardless of how well the COVID-19 vaccine and therapy prevent the disease from

spreading. The study did not consider the time delay in the transmission dynamics of COVID-19. The study formulated SVEIAHR mathematical model where the impact of model parameters on the spread of disease were examined through sensitivity analysis.

Jayaweera et al., (2020), in their study emphasized that forced social isolation and entire or partial lockdowns were effective ways to stop the virus from being transmitted. Their model showed that there was a significant time delay when people were subjected to mandatory social isolation. The crucial time interval between infection containment and transmission was two weeks. The mathematical model formulated uses a system of ordinary differential equations (ODE).

Aldila et al., (2020), in their study, considered the undiscovered asymptomatic individuals who actively contributed to the transmission of COVID-19 despite having no symptoms. The study also demonstrated that the inadequate healthcare resources contributed to the spread of COVID-19 virus. SVEIAHR mathematical model were developed, sensitivity analysis was used to determine how the model parameters affected the spread of the disease. The study found out that although it was necessary to reduced the basic reproductive number below one in order to stop the spread of infection, it was not sufficient because several additional intervention measures were required.

Lemaitre et al., (2020), in their study, the effects of non-pharmaceutical strategies, according to their studies, there was a significant amount of virus transmission through contaminated surfaces, depending on the nature of the virus. This study expressed concern about the fact that public awareness of COVID-19 was one of the main challenges in curbing the spread of COVID-19. Many people choose not to follow the safety precautions already in place including wearing face masks, regularly sanitizing, avoiding crowded areas and maintaining social distance. The mathematical model did not considered vaccination as the mitigation measure against the spread of COVID-19.

Shattock et al., (2022), studied the mathematical model based on ordinary differential equations (ODEs). Their study subdivided the total population into; susceptible, vaccinated, infectious, asymptomatic and recovered (SVIAR). Several simplifying assumptions were made in this

modeled scenarios. At the time of the study, the extent to which immunity wanes over time was not well understood, thus it assumed that no loss of naturally acquired or vaccine-induced immunity for the short period of simulation. It was important to monitor waning immunity for a period of 6 to 12-months after recovery or being vaccinated, as well as vaccine efficacy on novel variants. Vaccinating people under 18 years of age was not in progress since at that time, vaccine safety in children had not yet tested and delaying of second vaccine doses to increase coverage of first doses or because of dosing shortages were not explored, nor were third dose booster vaccines for those over 65 years of age were not approved at the time of their study. They did not consider potential changes in behavior among people once they were vaccinated. Their study showed that vaccinations contributed more to reduction in the transmission rate of COVID-19 compared to using NPIs strategy only, but did not state how the asymptomatic individuals affects the transmission dynamic of COVID-19 and the time delay.

### **2.3 Identification of the Knowledge Gap**

The above studies did not consider the time delay between asymptomatic and infectious time which requires the use of delay differential equations (DDEs) in modeling the transmission dynamics of COVID-19. Their numerical simulations indicated that COVID-19 could be controlled in the community with the implementation of nonpharmaceutical public health interventions such as face masks, hand washing and social distancing should continue to be encouraged. Also in presence of reinfection, if Kenya had increased the detection rate to those who were asymptomatic through contact tracing and isolating the positive cases, COVID-19 surge could have been curbed. Detection of asymptomatic cases during the period when Kenya was not vaccinating the general public on a large scale was effective in curbing COVID-19. These studies did not exhaustively considered the impact of both therapeutic and nontherapeutic measures on the dynamics of COVID-19. This study formulated a SVAIR mathematical model incorporating time delay for the transmission dynamics of COVID-19 in Kenya in which incubation period is considered.

## **CHAPTER THREE**

### **RESEARCH METHODOLOGY**


#### **3.1 Introduction**

This chapter outlines the methodology used in the thesis. First, the SVAIR model for COVID-19 is presented, model assumptions and equations are given. The model preliminary analysis, computation of the basic reproduction number, equilibrium points and stability analysis are provided. Finally, sensitivity analysis of the basic reproduction number on parameters is examined.

#### **3.2 SVAIR Model for COVID-19**

In order to formulate the model for the COVID-19 we describe the total population of humans by  $N(t)$  where the population was subdivided into five compartments for the SVAIR model namely: The susceptible (S) describes healthy people who have not yet been exposed to the COVID-19 virus. The vaccinated (V) are the susceptible individuals who have received COVID-19 vaccine, the infected asymptomatic (A), the symptomatic infected individuals (I) and the recovered (R) from COVID-19. The deterministic model that describes the transmission dynamics of COVID-19 in the community is shown by the following nonlinear delay differential equations (3.2):

### SVAIR Model Formulation



SVAIR Model Flow Diagram

### 3.3 Model Assumptions

The following are the assumptions useful in the derivation of the model.

- (i) There is homogeneous interaction of individuals in the population, which means that every individual who is uninfected has an equal chance of being infected provided he or she comes in contact with the infected individual.
- (ii) The recruitment rate into the susceptible class is constant  $p > 0$ .
- (iii) There is disease induced death and death due to natural causes.
- (iv) Dealing with closed population, no immigration nor emigration.

- (v) Permanent immunity upon vaccination is attainable.
- (vi) A fraction of asymptomatic individuals goes to infectious class.
- (vii) There is time lapse between exposure and being symptomatic.
- (viii) The rate of mortality is higher in infectious class followed by asymptomatic then recovered group and least in the vaccinated and susceptible class,  $\gamma_1 < \gamma_2 < \gamma_5 < \gamma_3 < \gamma_4$
- (ix) All the new borns are assumed to be susceptible.

Delay differential equations are used to develop the model because the incubation period causes the transition rates between compartments to be mathematically stated as derivatives. The deterministic nature of the illness transition and the differentiability of the population size in a compartment with regard to time are assumed when creating such models. Thus, a compartment's population changes can be computed based solely on the model's development history. The COVID-19 mathematical model is based on SVAIR transmission model in which the total population size  $N(t)$  is given by:

$$N(t) = S(t) + V(t) + A(t) + I(t) + R(t) \quad (3.1)$$

All newborns are assumed to be susceptible. The natural recruitment and the natural death are denoted by  $P$  and  $\gamma$  respectively. Susceptible individuals are vaccinated at constant rate  $\omega$ . The parameters  $\beta_1$  and  $\beta_2$  are the infecting rates of infectious and asymptomatic individuals respectively. The rate at which the infectious and asymptomatic individuals recovered and acquire temporary immunity is represented by  $\alpha$  and  $\delta_2$ .

The vaccinated individuals need a period of time to develop the immunity against the virus represented by  $\frac{1}{\varepsilon_3}$  and  $\frac{1}{\delta_1}$  represent the incubation period for asymptomatic individuals takes to develop symptoms. The virus may infect the vaccinated individuals but at a lower rate than the susceptible individuals who are not vaccinated. Based on the above assumptions and the model parameters, the transmission dynamics of COVID-19 is modeled by the following system of delay differential equations. The term with  $\varepsilon_3$  appears in the  $\frac{dV(t)}{dt}$  and  $\frac{dR(t)}{dt}$  equations is epidemiologically logical ,(Ismail et al., 2024)

### 3.4 Model Equations

using the model assumptions above, the SVAIR model equations are:

$$\left. \begin{aligned} \frac{dS(t)}{dt} &= p - \omega S - \beta_1 SI_\tau - \beta_2 SI_\tau - \gamma_1 S \\ \frac{dV(t)}{dt} &= \omega S - \varepsilon_1 V_\tau I_\tau - \varepsilon_2 V_\tau I_\tau - \varepsilon_3 V_\tau - \gamma_2 V \\ \frac{dA(t)}{dt} &= \beta_2 SI_\tau + \varepsilon_2 V_\tau I_\tau - \delta_1 A_\tau - \delta_2 A_\tau - \gamma_3 A \\ \frac{dI(t)}{dt} &= \beta_1 SI_\tau + \varepsilon_1 V_\tau I_\tau + \delta_1 A_\tau - \alpha I_\tau - (\gamma_4 + \mu) I \\ \frac{dR(t)}{dt} &= \alpha I_\tau + \delta_2 A_\tau + \varepsilon_3 V_\tau - \gamma_5 R \end{aligned} \right\} \quad (3.2)$$

where  $S(0) \geq 0$ ,  $V(0) \geq 0$ ,  $A(0) \geq 0$ ,  $I(0) \geq 0$  and  $R(0) \geq 0$  are the given initial states. Where  $p$  represents new birth rate into susceptible human population,  $\beta_2$  represents the transmission coefficient from susceptible individuals to asymptomatic infected cases,  $\omega$  represents the transmission coefficient from susceptible individuals to vaccinated class  $\gamma$  represents the natural death rate in all compartments.  $\delta_1$  represents the rate of transmission of asymptomatic infected cases to infected individuals with symptoms.  $\alpha$  is the transmission coefficient of the infectious cases to the recovered cases.  $\delta_2$  represents the rate of transmission of asymptomatic infected cases with mild symptoms to the recovered cases due the strong immunity of these individuals.  $\mu$  respectively represent the death rate of the infected individuals.  $\varepsilon_3$  represent the rate of progression from vaccinated class to recovery without being infected.

#### 3.4.1 Model Preliminary Analysis

#### 3.4.2 Positivity and Boundedness of the model

Positivity and boundedness of the model is shown before doing result analysis for equation 3.2 to be epidemiologically meaningful. Thus, we show that all state variables of the model (3.2) are nonnegative for all time  $t > 0$  and bounded and the existence of solutions are underscored by these properties.

Let  $C = C[-\tau, 0]$ ,  $\mathfrak{R}^5$  be a Banach space of continuous functions mapping the interval  $[-\tau, 0]$  into  $\mathfrak{R}^5$  with the topology of uniform convergence. By fundamental theory of differential equations

it can be shown that there exists a unique solution (  $S(t), V(t), A(t), I(t), R(t)$  ) of the system 3.2 with initial data.

$$(S(0) > 0, V(0) > 0, A(0) > 0, I(0) > 0, R(0) > 0 \in C) \quad (3.3)$$

In addition, we assume that the initial data for the system 3.2 satisfies;

$$S_0(p) \geq 0, V_0(p) \geq 0, A_0(p) \geq 0, I_0(p) \geq 0, R_0(p) \geq 0, \in [-\tau, 0] \quad (3.4)$$

The following theorem establishes the positivity and boundedness of the solution with initial functions satisfying (3.3) and (3.4)

**Theorem 3.1**

Let SVAIR be the solution of the system 3.2 satisfying the condition 3.3 and 3.4. then S,V,A,I and R are all positive and bounded for all  $t > 0$  at which the solution exist.

**Proof**

From the system 3.2 we have

$$S(t) = S(0)e^{-\int_0^t (\omega + \beta_1 I_\tau + \beta_2 I_\tau + \gamma_1) d\theta} + \int_0^t (p + (\omega + \beta_1 I_\tau + \beta_2 I_\tau + \gamma_1)) S(\varphi) e^{\int_0^t (\omega + \beta_1 I_\tau + \beta_2 I_\tau + \gamma_1) d\theta} d\varphi \quad (3.5)$$

From 3.5 it is clearly seen that  $S(t) > 0$  hence positive. Similarly, it can be shown that

$$V(t) > 0, A(t) > 0, I(t) > 0, R(t) > 0 \quad (3.6)$$

Using equation 3.3 and 3.4, positivity follows immediately from the above integral forms. For boundedness we define

$$N(t) = S(t) + V(t) + A(t) + I(t) + R(t) \quad (3.7)$$

$$\frac{dN(t)}{dt} = \frac{d(S(t) + V(t) + A(t) + I(t) + R(t))}{dt} \quad (3.8)$$

$$\frac{dN(t)}{dt} = p - \gamma(S(t) + V(t) + A(t) + I(t) + R(t)) \quad (3.9)$$

Thus

$$\frac{(dN(t))}{dt} \leq p - \Sigma \quad (3.10)$$

Where

$$\Sigma = \gamma S + \gamma V + \gamma A + \gamma I + \gamma R \quad (3.11)$$

This implies that  $N(t)$  is bounded and so are  $S(t)+V(t)+A(t)+I(t)+R(t)$ .

This completes the proof of theorem 3.1

### 3.5 Computation of Basic Reproduction Number $R_0$

Infections produced by a single infectious individual during the course of their infectious period are known as the basic reproduction number.  $R_0$  is the threshold value for infectious disease models because when  $R_0 < 1$ , the illness dies off, indicating that the disease free equilibrium state (DFE) is stable, when  $R_0 > 1$ , the DFE is unstable, meaning that the disease spread throughout the population.

In this study we adopted the next generation matrix (NGM) approach in computation of  $R_0$  such that  $R_0 = \rho FV^{-1}$  where  $\rho$  is the spectral radius for NGM while  $F$  is the matrix of new infection by the disease and  $V$  is the matrix of transfer of infection in and out of the compartment by other means. The dominant eigenvalue of the NGM is considered as  $R_0$ . In the equation 3.2, there are two infectious classes,  $A$  and  $I$  hence at disease free equilibrium, the matrix of new infection is given by matrix  $F$  and  $V$ .

Matrix  $F_i$  is obtained by considering the rate of new infections entering the compartment  $i$  is given by;

$$F_i = \begin{bmatrix} \beta_2 S I_\tau + \varepsilon_2 V_\tau I_\tau \\ \beta_1 S I_\tau + \varepsilon_1 V_\tau I_\tau + \delta_1 A_\tau \end{bmatrix} \quad (3.12)$$

The matrix that represents the rate of transfer into and out of compartment by other means at DFE is given by;

$$V_i = \begin{bmatrix} \delta_1 A_\tau + \delta_2 A_\tau + \gamma_3 A \\ \alpha I_\tau + (\gamma_4 + \mu) I \end{bmatrix} \quad (3.13)$$

We then differentiate  $F_i$  partially with respect to the state variables to obtain a 2x2 matrix

$$F_i = \begin{bmatrix} 0 & (\varepsilon_2 V_\tau + \beta_2 S)e^{-\lambda_\tau} \\ \delta_1 e^{-\lambda_\tau} & (\varepsilon_1 V_\tau + \beta_1 S)e^{-\lambda_\tau} \end{bmatrix} \quad (3.14)$$

Similarly, differentiating matrix  $V_i$  partially with respect to the state variables, we obtain a 2x2 matrix,

$$V_i = \begin{bmatrix} (\delta_1 + \delta_2)e^{-\lambda_\tau} + \gamma_3 & 0 \\ 0 & \alpha e^{-\lambda_\tau} + (\gamma_4 + \mu) \end{bmatrix} \quad (3.15)$$

The inverse of V is computed as

$$V^{-1} = \begin{bmatrix} \frac{1}{(\delta_1 + \delta_2)e^{-\lambda_\tau} + \gamma_3} & 0 \\ 0 & \frac{1}{\alpha e^{-\lambda_\tau} + (\gamma_4 + \mu)} \end{bmatrix} \quad (3.16)$$

Using the next generation matrix (NGM) to determine the basic reproduction number  $R_0$ , we have

$$NGM = FV^{-1} = \begin{bmatrix} 0 & \frac{(\varepsilon_2 V_\tau + \beta_2 S)e^{-\lambda_\tau}}{\alpha e^{-\lambda_\tau} + (\gamma_4 + \mu)} \\ \frac{\delta_1 e^{-\lambda_\tau}}{(\delta_1 + \delta_2)e^{-\lambda_\tau} + \gamma_3} & \frac{(\varepsilon_1 V_\tau + \beta_1 S)e^{-\lambda_\tau}}{\alpha e^{-\lambda_\tau} + (\gamma_4 + \mu)} \end{bmatrix} \quad (3.17)$$

To determine the eigenvalues, we have the characteristic matrix of  $FV^{-1}$  given by;

$$\begin{vmatrix} -\lambda & \frac{(\varepsilon_2 V_\tau + \beta_2 S)e^{-\lambda_\tau}}{\alpha e^{-\lambda_\tau} + (\gamma_4 + \mu)} \\ \frac{\delta_1 e^{-\lambda_\tau}}{(\delta_1 + \delta_2)e^{-\lambda_\tau} + \gamma_3} & \frac{(\varepsilon_1 V_\tau + \beta_1 S)e^{-\lambda_\tau}}{\alpha e^{-\lambda_\tau} + (\gamma_4 + \mu)} - \lambda \end{vmatrix} = 0 \quad (3.18)$$

Solving for the eigenvalues we obtain;

$$\lambda_2 = \frac{(\varepsilon_1 V_\tau + \beta_1 S)e^{-\lambda_\tau}}{\alpha e^{-\lambda_\tau} + (\gamma_4 + \mu)} \quad (3.19)$$

The dominant eigenvalue is;

$$\lambda_2 = \frac{(\varepsilon_1 V_\tau + \beta_1 S)e^{-\lambda_\tau}}{\alpha e^{-\lambda_\tau} + (\gamma_4 + \mu)} \quad (3.20)$$

The  $R_0$  which is the dominant eigenvalue is given by;

$$\text{Therefore, } R_0 = \frac{(\varepsilon_1 V_\tau + \beta_1 S)e^{-\lambda_\tau}}{\alpha e^{-\lambda_\tau} + (\gamma_4 + \mu)} \quad (3.21)$$

### 3.6 Disease Free Equilibrium Point and its Stabilities

We investigate the stability of equation 3.2 in order to have a good understanding of the dynamics of COVID-19. The Disease Free Equilibrium Point (DFE) and the Endemic Equilibrium Point (EEP) are the two equilibria points taken into account in mathematical epidemiology. In this study, we examined the stabilities of the disease-free equilibrium found in equation 3.2.

An equilibrium point is determined by setting the right-hand side of each equation 3.2 to zero, then solving each equation for the constant solution. Disease free equilibrium point is a feasible region in the solution of equation 3.2 in the absence of viral infection.

For the model equation 3.2, DFE is set of  $S(0), V(0), A(0), I(0), R(0) = (\frac{p}{\omega + \beta_1 I_\tau + \beta_2 I_\tau + \gamma_1}, 0, 0, 0, 0)$  obtained by simple algebraic computation in the absence of COVID-19 viruses.

#### 3.6.1 Local Stability of Disease Free Equilibrium

The model's variable state when there is no disease is known as the disease-free equilibrium. The eigenvalues of the Jacobian matrix formed during DFE, where the reproduction number is less than one  $R_0 < 1$ , can be used to assess the stability. Deduced from the first partial derivatives of equation 3.2 and derived from compartmental classes, the Jacobian matrix is provided by;

$$\left. \begin{aligned} p - \omega S - \beta_1 S I_\tau - \beta_2 S I_\tau - \gamma_1 S &= 0 \\ \omega S - \varepsilon_1 V_\tau I_\tau - \varepsilon_2 V_\tau I_\tau - \varepsilon_3 V_\tau I_\tau - \gamma_2 V &= 0 \\ \beta_2 S I_\tau + \varepsilon_2 V_\tau I_\tau - \delta_1 A_\tau - \delta_2 A_\tau - \gamma_3 A &= 0 \\ \beta_1 S I_\tau + \varepsilon_1 V_\tau I_\tau + \delta_1 A_\tau - \alpha I_\tau - (\gamma_4 + \mu) I &= 0 \\ \alpha I_\tau + \delta_2 A_\tau + \varepsilon_3 V_\tau I_\tau - \gamma_5 R &= 0 \end{aligned} \right\} \quad (3.22)$$

The linearization matrix is given by;

$$\begin{bmatrix} -(\omega + \beta_1 I_\tau + \beta_2 I_\tau + \gamma_1) & 0 & 0 & 0 & 0 \\ \omega & -(\varepsilon_1 + \varepsilon_2 + \varepsilon_3)I_\tau e^{-\lambda_\tau} - \gamma_2 & 0 & -(\varepsilon_1 + \varepsilon_2 + \varepsilon_3)v_\tau e^{-\lambda_\tau} & 0 \\ \beta_2 I_\tau & \varepsilon_2 I_\tau e^{-\lambda_\tau} & -(\delta_1 + \delta_2)e^{-\lambda_\tau} - \gamma_3 & (\beta_2 S + \varepsilon_2 V_\tau)e^{-\lambda_\tau} & 0 \\ \beta_1 I_\tau & \varepsilon_1 I_\tau e^{-\lambda_\tau} & \delta_1 e^{-\lambda_\tau} & Q & 0 \\ 0 & \varepsilon_3 I_\tau e^{-\lambda_\tau} & \delta_2 e^{-\lambda_\tau} & (\alpha + \varepsilon_3 v_\tau)e^{-\lambda_\tau} & -\gamma_5 \end{bmatrix} \quad (3.23)$$

Where  $Q = -(\alpha - \beta_1 s - \varepsilon_1 v_\tau)e^{-\lambda_\tau} - (\gamma_4 + \mu)$

The equation 3.2 is locally asymptotically stable if all the eigenvalues of the linearization matrix of the equation 3.2 are negative.

$$\begin{vmatrix} A - \lambda & 0 & 0 & 0 & 0 \\ \omega & B - \lambda & 0 & -(\varepsilon_1 + \varepsilon_2 + \varepsilon_3)v_\tau e^{-\lambda_\tau} & 0 \\ \beta_2 I_\tau & \varepsilon_2 I_\tau e^{-\lambda_\tau} & C - \lambda & (\beta_2 S + \varepsilon_2 V_\tau)e^{-\lambda_\tau} & 0 \\ \beta_1 I_\tau & \varepsilon_1 I_\tau e^{-\lambda_\tau} & \delta_1 e^{-\lambda_\tau} & D - \lambda & 0 \\ 0 & \varepsilon_3 I_\tau e^{-\lambda_\tau} & \delta_2 e^{-\lambda_\tau} & (\alpha + \varepsilon_3 v_\tau)e^{-\lambda_\tau} & E - \lambda \end{vmatrix} \quad (3.24)$$

Where;

$$\left. \begin{aligned} A &= -(\omega + \beta_1 I_\tau + \beta_2 I_\tau + \gamma_1) \\ B &= -(\varepsilon_1 + \varepsilon_2 + \varepsilon_3)I_\tau e^{-\lambda_\tau} - \gamma_2 \\ C &= -(\delta_1 + \delta_2)e^{-\lambda_\tau} - \gamma_3 \\ D &= -(\alpha - \beta_1 s - \varepsilon_1 v_\tau)e^{-\lambda_\tau} - (\gamma_4 + \mu) \\ E &= -\gamma_5 \end{aligned} \right\} \quad (3.25)$$

The eigenvalues are;

$$\left. \begin{aligned} \lambda_{**1} &= -(\omega + \beta_1 I_\tau + \beta_2 I_\tau + \gamma_1) \\ \lambda_{**2} &= -(\varepsilon_1 + \varepsilon_2 + \varepsilon_3) I_\tau e^{-\lambda_\tau} - \gamma_2 \\ \lambda_{**3} &= -(\delta_1 + \delta_2) e^{-\lambda_\tau} - \gamma_3 \\ \lambda_{**4} &= -(\alpha - \beta_1 S - \varepsilon_1 v_\tau) e^{-\lambda_\tau} - (\gamma_4 + \mu) \\ \lambda_{**5} &= -\gamma_5 \end{aligned} \right\} \quad (3.26)$$

For the equation 3.2, it is clear that the dominant eigenvalue is;

$$\lambda_{**4} = -(\alpha - \beta_1 S - \varepsilon_1 v_\tau) e^{-\lambda_\tau} - (\gamma_4 + \mu) \quad (3.27)$$

### Theorem 3.2

Disease free equilibrium is stable whenever  $R_0 < 1$ , otherwise it's unstable.

#### Proof

$\lambda_{**4}$  should be negative. This can only be negative if,

$$\begin{aligned} -(\alpha - \beta_1 S - \varepsilon_1 v_\tau) e^{-\lambda_\tau} - (\gamma_4 + \mu) &= 0 \\ (\beta_1 S + \varepsilon_1 v_\tau) e^{-\lambda_\tau} &< \alpha e^{-\lambda_\tau} + (\gamma_4 + \mu) \end{aligned} \quad (3.28)$$

This implies that;

$$\frac{(\beta_1 S + \varepsilon_1 v_\tau) e^{-\lambda_\tau}}{\alpha e^{-\lambda_\tau} + (\gamma_4 + \mu)} < 1 \quad (3.29)$$

Therefore  $R_0 < 1$  is obtained for DFE to be stable.

### 3.6.2 Global stability analysis of disease free equilibrium points

Global stability of the equation 3.2 was done by constructing Lyapunov functions for disease free equilibrium point.

#### Theorem 3.3

If  $R_0 < 1$  then the disease free equilibrium of the equation 3.2 is globally asymptotically stable, otherwise it is unstable for  $R_0 > 1$ .

**Proof**

Consider the following Lyapunov functions;

$$V(S, V, A, I, R) = (S - S_0)^2 + (V - 0)^2 + (A - 0)^2 + (I - 0)^2 + (R - 0)^2 \quad (3.30)$$

$$= (S - S_0)^2 + (V)^2 + (A)^2 + (I)^2 + (R)^2 \quad (3.31)$$

For the equation 3.2, we have

$$p - \omega S - \beta_1 S I_\tau - \beta_2 S I_\tau - \gamma_1 S = 0 \quad (3.32)$$

This implies;

$$S = \frac{p}{\omega + \beta_1 I_\tau + \beta_2 I_\tau + \gamma_1} \quad (3.33)$$

Implying that  $S > 0$  hence positive.

It follows that

$$V = V_n = A = I = R > 0 \quad (3.34)$$

The derivative of the equation 3.2 with respect to time is given as;

$$\frac{dV}{dt}(S, V, A, I, R) = 2(S - S_0) \frac{dS}{dt} + 2V \frac{dV}{dt} + 2A \frac{dA}{dt} + 2I \frac{dI}{dt} + 2R \frac{dR}{dt} \quad (3.35)$$

At disease free equilibrium point,  $V = V_n = A = I = R = 0$ , therefore equation (3.35) above becomes;

$$V^1 = 2(S - S_0) \quad (3.36)$$

For global stability,  $S < S_0$  so that  $V^1 < 0$ .

If  $S \leq S_0$  then  $V^1 \leq 0$  implying that  $R_0 \leq 1$ , implying the disease free equilibrium point is globally stable.

### 3.7 The Endemic Equilibrium Point

In this section, we study the conditions for the existence of endemic equilibrium point for equation 3.2. The analysis of the equilibrium point is done at the critical point of equation 3.2 which exist

when  $S > 0, V > 0, A > 0, I > 0, R > 0$ . The zero solution of the nonlinear equation 3.2 at EEP is asymptotically stable if and only if the zero solutions of the linear system obtain from equation 3.2 is asymptotically stable. Therefore, the asymptotic stability of equation 3.2 at EEP is established by examining the signs of the eigenvalues of the zero solutions of the linearized system.

$$\left. \begin{aligned} p - \omega S - \beta_1 S I_\tau - \beta_2 S I_\tau - \gamma_1 S &= 0 \\ \omega S - \varepsilon_1 V_\tau I_\tau - \varepsilon_2 V_\tau I_\tau - \varepsilon_3 V_\tau I_\tau - \gamma_2 V &= 0 \\ \beta_2 S I_\tau + \varepsilon_2 V_\tau I_\tau - \delta_1 A_\tau - \delta_2 A_\tau - \gamma_3 A &= 0 \\ \beta_1 S I_\tau + \varepsilon_1 V_\tau I_\tau + \delta_1 A_\tau - \alpha I_\tau - (\gamma_4 + \mu) I &= 0 \\ \alpha I_\tau + \delta_2 A_\tau + \varepsilon_3 V_\tau I_\tau - \gamma_5 R &= 0 \end{aligned} \right\} \quad (3.37)$$

Defining the endemic equilibrium point as;

$E = S^*, V^*, A^*, I^*, R^*$  which satisfies system 3.37. Then with simple algebraic calculations we obtain the values of endemic equilibrium points as;

$$\left. \begin{aligned} S^* &= \frac{p}{\omega + \beta_1 I_\tau + \beta_2 I_\tau + \gamma_1} \\ V^* &= \frac{\frac{\omega p}{\omega + \beta_1 I_\tau + \beta_2 I_\tau + \gamma_1} - (\varepsilon_1 + \varepsilon_2 + \varepsilon_3) V_\tau I_\tau}{\gamma_2} \\ A^* &= \frac{\frac{\beta_2 I_\tau p}{\omega + \beta_1 I_\tau + \beta_2 I_\tau + \gamma_1} + \varepsilon_2 V_\tau I_\tau - (\delta_1 + \delta_2) A_\tau}{\gamma_3} \\ I^* &= \frac{\frac{\beta_1 I_\tau p}{\omega + \beta_1 I_\tau + \beta_2 I_\tau + \gamma_1} + \varepsilon_1 V_\tau I_\tau + \delta_1 A_\tau - \alpha I_\tau}{(\gamma_4 + \mu)} \\ R^* &= \frac{\alpha I_\tau + \delta_2 A_\tau + \varepsilon_3 V_\tau I_\tau}{\gamma_5} \end{aligned} \right\} \quad (3.38)$$

#### 3.7.1 Stability of endemic equilibrium point

The EEP is guaranteed to be stable, when all of the linearization matrix's eigenvalues for EEP are negative, equation 3.2 is considered locally asymptotically stable. It is necessary to convert the

equilibrium points to the origin for stability analysis. In order to begin, we centralize equation 3.2 at the endemic equilibrium  $E(S^*, V^*, A^*, I^*, R^*)$  by introducing new variables.

$$\left. \begin{aligned} L_1 &= S - S^* \\ L_2 &= V - V^* \\ L_3 &= A - A^* \\ L_4 &= I - I^* \\ L_5 &= R - R^* \end{aligned} \right\} \quad (3.39)$$

We then rewrite model equation 3.2 in terms of the new variables and because  $E(S^*, V^*, A^*, I^*, R^*)$  is an equilibrium point, the constant terms cancel. We also discard the quadratic terms because their partial derivatives at the origin is zero. The equation 3.2 with the new variables becomes;

$$\left. \begin{aligned} L_1^* &= p - (\omega + \beta_1 I_\tau + \beta_2 I_\tau + \gamma_1)(L_1 + S^*) \\ L_2^* &= \omega(L_1 + S^*) - (\epsilon_1 I_\tau + \epsilon_2 I_\tau + \epsilon_3 I_\tau)(L_2 + V_\tau^*) - \gamma_2(L_2 + V^*) \\ L_3^* &= \beta_2 I_\tau(L_1 + S^*) + \epsilon_2 I_\tau(L_2 + V_\tau^*) - (\delta_1 + \delta_2)(L_3 + A_\tau^*) - \gamma_3(L_3 + A^*) \\ L_4^* &= \beta_1 I_\tau(L_1 + S^*) + \epsilon_1 I_\tau(L_2 + V_\tau^*) + \delta_1(L_3 + A_\tau^*) - \alpha(L_4 + I_\tau^*) - (\gamma_4 + \mu)(L_4 + I^*) \\ L_5^* &= \alpha(L_4 + I_\tau^*) + \delta_2(L_3 + A_\tau^*) + \epsilon_3 I_\tau(L_2 + V_\tau^*) - \gamma_5(L_5 + R^*) \end{aligned} \right\} \quad (3.40)$$

A solution of the form  $L(t) = L_0 e^{-\lambda t}$  and equation 3.40 is linearized about the equilibrium  $(L_1, L_2, L_3, L_4, L_5) = (S^*, V^*, A^*, I^*, R^*)$  to obtain;

$$L^{*'}(t) = BL^*(t) \quad (3.41)$$

Where B is a 5×5 matrix. Differentiating the expanded equations of equation 3.40 partially with respect to the state variables, we obtain a 5×5 matrix Jacobian  $J_2$ , and is given as;

$$\begin{bmatrix} -(\omega + \beta_1 I_\tau + \beta_2 I_\tau + \gamma_1) & 0 & 0 & 0 & 0 \\ \omega & -I_\tau(\varepsilon_1 + \varepsilon_2 + \varepsilon_3)e^{-\lambda_\tau} - \gamma_2 & 0 & 0 & 0 \\ \beta_2 I_\tau & \varepsilon_2 I_\tau e^{-\lambda_\tau} & -(\delta_1 + \delta_2)e^{-\lambda_\tau} - \gamma_3 & 0 & 0 \\ \beta_1 I_\tau & \varepsilon_1 I_\tau e^{-\lambda_\tau} & \delta_1 e^{-\lambda_\tau} & -(\gamma_4 + \mu + \alpha e^{-\lambda_\tau}) & 0 \\ 0 & \varepsilon_3 I_\tau e^{-\lambda_\tau} & \delta_2 e^{-\lambda_\tau} & \alpha e^{-\lambda_\tau} & -\gamma_5 \end{bmatrix} \quad (3.42)$$

The characteristic equation of the Jacobian matrix is given by;  $|J - I\lambda| = 0$ , where  $I$  is 5×5 identity matrix. To find the eigenvalues we have;

$$\begin{vmatrix} A - \lambda & 0 & 0 & 0 & 0 \\ \omega & B - \lambda & 0 & 0 & 0 \\ \beta_2 I_\tau & \varepsilon_2 I_\tau e^{-\lambda_\tau} & C - \lambda & 0 & 0 \\ \beta_1 I_\tau & \varepsilon_1 I_\tau e^{-\lambda_\tau} & \delta_1 e^{-\lambda_\tau} & D - \lambda & 0 \\ 0 & \varepsilon_3 I_\tau e^{-\lambda_\tau} & \delta_2 e^{-\lambda_\tau} & \alpha e^{-\lambda_\tau} & E - \lambda \end{vmatrix} = 0 \quad (3.43)$$

Where;

$$\left. \begin{aligned} A &= -(\omega + \beta_1 I_\tau + \beta_2 I_\tau + \gamma_1) \\ B &= -I_\tau(\varepsilon_1 + \varepsilon_2 + \varepsilon_3)e^{-\lambda_\tau} - \gamma_2 \\ C &= -(\delta_1 + \delta_2)e^{-\lambda_\tau} - \gamma_3 \\ D &= -(\gamma_4 + \mu + \alpha e^{-\lambda_\tau}) \\ E &= -\gamma_5 \end{aligned} \right\} \quad (3.44)$$

The equation 3.40 is locally asymptotically stable if all the eigenvalues of the linearization matrix of equation 3.40 are negative. Therefore the eigenvalues are;

$$\left. \begin{aligned} \lambda_{***1} &= -(\omega + \beta_1 I_\tau + \beta_2 I_\tau + \gamma_1) \\ \lambda_{***2} &= -I_\tau(\varepsilon_1 + \varepsilon_2 + \varepsilon_3)e^{-\lambda_\tau} - \gamma_2 \\ \lambda_{***3} &= -(\delta_1 + \delta_2)e^{-\lambda_\tau} - \gamma_3 \\ \lambda_{***4} &= -(\gamma_4 + \mu + \alpha e^{-\lambda_\tau}) \\ \lambda_{***5} &= -\gamma_5 \end{aligned} \right\} \quad (3.45)$$

The existence of endemic equilibrium is determined by the existence of positive solutions of the quadratic equation. Using  $\lambda_{***3}$  and  $\lambda_{***4}$  being the dominant eigenvalues, we obtain the characteristics equation below;

$$[((\varepsilon_1 + \varepsilon_2 + \varepsilon_3)e^{-\lambda\tau} - \gamma_2) - \lambda][((\delta_1 + \delta_2)e^{-\lambda\tau} - \gamma_3) - \lambda] = 0 \quad (3.46)$$

$$(x - \lambda)(y - \lambda) = 0$$

Where,

$$x = ((\varepsilon_1 + \varepsilon_2 + \varepsilon_3)e^{-\lambda\tau} - \gamma_2)$$

$$y = ((\delta_1 + \delta_2)e^{-\lambda\tau} - \gamma_3)$$

This implies,

$$\lambda^2 - (x + y)\lambda + xy = 0 \quad (3.47)$$

Which simplifies as;

$$a\lambda^2 - b\lambda + c = 0 \quad (3.48)$$

Therefore , the reproduction number at EEP is given by;

$$\lambda_{***} = \frac{-b \pm \sqrt{(b^2 - 4ac)}}{2a}$$

$$R_0 = \lambda_{***} = \frac{-b + \sqrt{(b^2 - 4c)}}{2} \quad (3.49)$$

Clearly,

$$R_0 = \frac{b^2}{(b^2 - 4c)} > 1 \quad (3.50)$$

The basic reproduction number at EEP is greater than one ( $R_0 > 1$ ), which implies that the disease existence persists and is therefore endemic.

## CHAPTER FOUR

### RESULTS AND DISCUSSION

#### 4.1 Introduction

In this chapter, numerical simulation were carried out using MATLAB to verify the analytic results on stability of model equations 3.2 considered in chapter three. The values for the parameters were taken from the literature. In simulation of the model equations 3.2, the following initial values in each compartment at the onset of infection is assumed to apply;  $(S(0), V(0), A(0), I(0), R(0)) = (5.036 \times 10^7, 0, 0, 0, 0)$  on the interval  $[-\tau, 0]$ .

#### 4.2 Numerical Simulations and Discussions

In the numerical solution, we used MATLAB to plot the system of Equation (3.2) to verify the analytical results on the stability of the model. The plot gives us an idea of how the different compartment of people; susceptible, vaccinated, asymptomatic infected, or recovered, rise or fall during a period of weeks. Figure 4.1 illustrates the smooth curve, representing susceptibility with time which drastically decreases within the first 150 days then stabilized after. Figure 4.2 represents the smooth curve for the vaccinated against time, which rose slowly due to vaccine shortage within the first 150 days then steadily rose. The figure 4.3 represents the smooth curve for recovery with time, which rose steadily within the first 150 days before it stabilized because of increased vaccination coverage. Figure 4.4 represents the infections with time, the number of infections rose to the peak in the first 200 days then gradually decreased. First, everyone is susceptible, then the number decrease and some of the infected progress to asymptomatic or infectious class but after a series of weeks, the infected becomes sick, but they recovery from the disease or die.


Numerical simulations of the model equations are obtained using the list of parameters and the estimated values given in Table 4.1

**Table 4.1:** Table of parameters, parameter description, values and source

Table 4.1 Table of parameters and values


| Parameter                 | Description                                            | Value                                    | Source                                        |
|---------------------------|--------------------------------------------------------|------------------------------------------|-----------------------------------------------|
| S                         | Susceptible class                                      | $5.036 \times 10^7 \text{ years}^{-1}$   | Estimated from (Muchiri <i>et al.</i> , 2022) |
| V                         | Coronavirus disease vaccinated class                   | $1.8 \times 10^7 \text{ years}^{-1}$     | (Carpio <i>et al.</i> , 2021)                 |
| A                         | Asymptomatic infected class                            | $7322 \text{ years}^{-1}$                | (Carpio <i>et al.</i> , 2021)                 |
| I                         | Symptomatic infected class                             | $7545 \text{ years}^{-1}$                | Estimated from (Muchiri <i>et al.</i> , 2022) |
| R                         | Recovered class                                        | $203968 \text{ years}^{-1}$              | Estimated from (Muchiri <i>et al.</i> , 2022) |
| p                         | Recruitment rate                                       | $1762 \text{ days}^{-1}$                 | Estimated from (Muchiri <i>et al.</i> , 2022) |
| $\omega$                  | Rate of progression from S to V                        | $0.002 \text{ days}^{-1}$                | Assumed                                       |
| $\beta_1$                 | Transition rate from susceptible to infectious class   | $0.233 \text{ days}^{-1}$                | (Chae <i>et al.</i> , 2020)                   |
| $\beta_2$                 | Transition rate from susceptible to asymptomatic class | $0.09786 \text{ days}^{-1}$              | (Algarni <i>et al.</i> , 2022)                |
| $\varepsilon_1$           | Rate of progression from V to I                        | $0.462 \text{ days}^{-1}$                | (Chae <i>et al.</i> , 2020)                   |
| $\varepsilon_2$           | Rate of progression from V to A                        | $0.039 \text{ days}^{-1}$                | (Li <i>et al.</i> , 2020)                     |
| $\frac{1}{\varepsilon_3}$ | Immunity development period                            | $0.0714 \text{ days}^{-1}$               | (Algarni <i>et al.</i> , 2022)                |
| $\delta_1$                | Rate of progression from A to I                        | $0.1428 \text{ days}^{-1}$               | (Algarni <i>et al.</i> , 2022)                |
| $\delta_2$                | Rate of progression from A to R                        | $0.165 \text{ days}^{-1}$                | (Buonomo <i>et al.</i> , 2022)                |
| $\alpha$                  | Rate of progression from I to R                        | $0.1 \text{ days}^{-1}$                  | (Algarni <i>et al.</i> , 2022)                |
| $\gamma$                  | Natural death rate                                     | $1.07 \times 10^{-2} \text{ years}^{-1}$ | (Buonomo <i>et al.</i> , 2022)                |
| $\mu$                     | Disease induced death rate                             | $6.248 \times 10^{-4} \text{ days}^{-1}$ | (Buonomo <i>et al.</i> , 2022)                |
| $\tau$                    | Time delay                                             | To be estimated                          |                                               |

### SVAIR Model Population vs Time(days)



A plot of Susceptible Population against time (days)


From the graph in the **Figure 4.1** above , it is evident that susceptible population is inversely proportional to time, nearly the entire population were susceptible from the onset then drastically decreases.  $S(t)$  decreases over time steeply at first then levels off near the end as the epidemic slows. The sharp drop was due to the rising number of infection cases and the stabilized at the lower level was because increased vaccination coverage which boost the immune protection.



A plot of Vaccinated population against time (days)

From the graph **Figure 4.2** above, it is evident that vaccinated individuals are directly proportional to time. The number of vaccinated individuals gradually increases.


A solution to COVID-19 could be achieved when we increased the number of vaccinated people to half or more of the population. These results reduced the number of infected people and increased the number of susceptible individuals.



A plot of Recovered against Time

From the graph **Figure 4.3** above, it is evident that the number of recovered individuals is directly proportional to time. Recovered individuals increases because of increased vaccination coverage.

Following a period of infection, surviving individuals recovered to a state in which viral shedding no longer occurs. These recovered individuals are assumed to be susceptible to reinfection but are assumed to retain some level of partial immunity, which reduces susceptibility to subsequent exposure. Gradual loss of protection against infection over time may result in immunity decay, but for this study we optimistically assume no immunity decay following naturally acquired or vaccine-induced immunity due to the short-term nature of the simulation period. For naturally acquired immunity due to infection, we assumed an 90% transmission blocking effect when or if re-exposed (Shattock et al., 2022). If a previously infected but recovered individual is later vaccinated, the level of transmission blocking immunity is taken to be the highest of the two independent effects. No combined resultant effect was considered. Although the transmission blocking effect of naturally acquired immunity and vaccine-induced-acquired immunity can be of different strengths, they are both considered enhancing the immune state of an individual.




A plot of Infectious against Time

From the graph **Figure 4.4** above, it is evident that the rate of infections rose with time to the peak. Increased in number due to absent of vaccination and gradually decreased when vaccination started which caused delayed infections.

Early phase, infections start low and increase exponentially because many people are susceptible. The peak phase demonstrates that infection growth slows as more people develop immune naturally or due to vaccines, the curve reaches maximum point called the epidemic peak. The decline phase; infections decrease as fewer susceptible individuals remain and the number of recovered reduces the spread of COVID-19. The end phase; the curve flattens or stabilizes at a lower endemic level meaning there was less infections but more vaccination coverage. Figure 4.1 shows the dynamics of population of various compartments of SVAIR against time in days. From the graph, it is evident that nearly the entire population is susceptible from the onset and as the infected number increases, the number of susceptible individuals drastically decreases to about 20 percent, because vaccination, treatment and time delay played a major role in stabilizing the rate of infection. Increasing vaccination coverage means immunity of the susceptible individual is improved hence the infectious period delayed and therefore the basic reproduction number is lowered, minimizing the rate of infection.


### 4.3 Analysis of Basic Reproduction Number at DFE and EEP

At Disease Free Equilibrium (DFE),  $R_0 < 1$  which implies that the disease dies out in the population. Public health interventions aim at reducing and maintaining the value of  $R_0$  below 1 which can be attained through vaccination which lowers the rate of infection by increasing time delay hence  $R_0$  is reduced.




$R_0$  against Death rate due to COVID-19 ( $\mu$ )

**Figure 4.5** above shows that the reproduction number  $R_0$  is directly proportion to the rate of death. It is evident from the graph that when the number of individuals with the disease is high, those who die also goes up and vice versa unless intervention measure like vaccination is rolled out which lowers the spread by increasing time delay hence  $R_0$  is reduced resulting in reduced death rate.




$R_0$  against Gamma ( $\gamma$ )

**Figure 4.6** above shows a plot of reproduction number against the natural death rate. It is evident that  $R_0$  is inversely proportional to the natural death rate, when the natural death rate ( $\gamma$ ) is high it reduces the effective reproduction number  $R_0$  slightly as some infected individuals die before transmitting the virus.



$R_0$  against Delta ( $\delta$ )

**Figure 4.7:** above shows a plot of reproduction number against the rate of progression from asymptomatic (A) to infectious (I). It is evident that  $R_0$  is directly proportional to the rate of progression  $\delta$ . A higher progression rate ( $\delta A$ ) implies a shorter asymptomatic infectious period (incubation period) this potentially increasing  $R_0$ .



$R_0$  against Time delay ( $\tau$ )

**Figure 4.8** above shows a plot of reproduction number against time delay at DFE. From the graph  $R_0$  is inversely proportional to time delay. It is evident that a shorter  $\tau$  leads to higher  $R_0$  and the virus spread faster in a population. If  $\tau$  is short, highly contagious variants spread faster before intervention measures can take effect.

#### 4.4 Sensitivity Analysis of Basic Reproduction Number $R_0$

Sensitivity analysis for the basic reproduction number  $R_0$  is being studied in order to identify the parameter value that has the greatest impact on the spread of the disease. Because of this, we must ascertain the reproduction number's sensitivity index in relation to the model parameters. Sensitivity index analysis is done using partial derivatives when the variable is a differentiable function of the parameter, (Adebiyi et al., 2016)

Through the examination of these indices, the most important parameter for the dynamics of COVID-19 transmission was identified. The ratio of the relative change in a variable to the relative change in a parameter is known as the normalized forward sensitivity index, (Adebiyi et

al .., 2016) Sensitivity index is defined using partial derivative as;

$$\eta = \frac{\partial R_o}{\partial x} \times \frac{x}{R_o} \quad (4.1)$$

where,

$\eta$  is the sensitivity index

$R_o$  is the basic reproduction number

$x$  is the parameter under investigation

Therefore the derivation of the sensitivity index  $\eta$  of  $R_o$  with respect to each parameter is given below.

$$\frac{\partial R_o}{\partial \gamma} \times \frac{\gamma}{R_o} = \frac{-\gamma}{\delta_1 + \gamma + \mu} = -0.06942$$

$$\frac{\partial R_o}{\partial \mu} \times \frac{\mu}{R_o} = \frac{-\mu}{\delta_1 + \gamma + \mu} = -0.004054$$

$$\frac{\partial R_o}{\partial \alpha} \times \frac{\alpha}{R_o} = \frac{-\alpha}{\delta_1 + \gamma + \mu} = 0.6488$$

$$\frac{\partial R_o}{\partial \delta_1} \times \frac{\delta_1}{R_o} = \frac{-\delta_1}{\delta_1 + \gamma + \mu} = 0.9265$$

The sensitivity indices for the parameters in our model are as shown in the table 4.2 below.

Table 4.2 Table of parameters, parameter description, values and sensitivity indices of  $R_o$

| Parameter  | Parameter description                                   | Value                         | Sensitivity |
|------------|---------------------------------------------------------|-------------------------------|-------------|
| $\gamma$   | Natural death rate                                      | 0.0107 days <sup>-1</sup>     | - 0.06942   |
|            |                                                         | 0.005 days <sup>-1</sup>      | - 0.04744   |
| $\mu$      | Disease induced death rate                              | 0.0006248 years <sup>-1</sup> | - 0.004054  |
|            |                                                         | 0.0004 years <sup>-1</sup>    | - 0.003795  |
| $\alpha$   | Recovery rate of infectious class                       | 0.1 days <sup>-1</sup>        | - 0.6488    |
|            |                                                         | 0.05 days <sup>-1</sup>       | - 0.4744    |
| $\delta_1$ | Rate of progression of asymptomatic to infectious class | 0.1428 days <sup>-1</sup>     | - 0.9265    |
|            |                                                         | 0.12 days <sup>-1</sup>       | - 0.8547    |

Sources of parameter values:(Algarni et al., 2022)

From table 4.2, it is evident that for all model parameters, the signs of the sensitivity indices of  $R_o$  are all negative. This implies that all model parameters under consideration contributes to the decline in the spread of the COVID-19 infection. It is all notable that  $\delta_1$  is more sensitive than

other model parameters since it gives the most negative sensitivity index. Thus  $\delta_1$ , which is rate of progression of asymptomatic individuals to infectious class, contributes more to the decline in the spread and transmission of COVID-19 infection.

## CHAPTER FIVE

### CONCLUSION, RECOMMENDATIONS AND SUGGESTIONS FOR FURTHER RESEARCH

#### 5.1 Introduction

This chapter gives an overview of the thesis, it outlines the summary of the key findings and highlights the general conclusion. Finally the recommendations and suggestions for further research work.

#### 5.2 Conclusion

In this study, we formulated and presented a SVAIR mathematical model of COVID-19 transmission dynamics, incorporating time delay. An expression of the basic reproduction number was derived from the model equation (3.2). Stability analysis of equilibrium points of the model was determined where, it was found out that the model was stable at both Disease Free Equilibrium (DFE) and Endemic Equilibrium Point (EEP) and was attained when  $R_0 < 1$  and  $R_0 > 1$  respectively. The parameter values were taken from the literature and the analytical findings were verified numerically using the Matlab dde 23 solver. From the study it is evident that for time delay  $\tau > 5$  days DFE is stable otherwise unstable. Numerical simulation was carried out to validate the analytic results where it was found out that  $R_0 = 0.95$  at DFE. Furthermore the results show that stability was guaranteed at EEP and is attained at  $R_0 = 1.02$ . Time delay, rate of vaccination and rate of progression from asymptomatic to infectious plays an important role in the transmission of COVID-19 and stability at DFE and EEP. The sensitivity analysis of the model parameters were performed to identify the parameter that has the greatest impact on the reproduction number  $R_0$ , it was found out that for all model parameters under study, the signs

of the sensitivity indices of  $R_0$  were all negative. This implied that the model parameters under consideration contributed to the decline in the spread of the COVID-19 infection. It was noted that the rate of progression from asymptomatic to infectious  $\delta_1$  was more sensitive than other model parameters since it contributed the most negative sensitivity index of -0.9265.

### **5.3 Recommendations**

In our study on COVID-19 outbreak in Kenya, numerical simulation shows that incubation period for asymptomatic individuals was 5 days. This recommends it necessary to prolong the time delay by increasing the vaccination coverage against COVID-19 so that all potentially infected asymptomatic individuals progress to recovery class. The time delay was substantially shorter, suggesting that a significant number of secondary transmission may occur prior to illness onset. Also based on the high sensitivity index  $\delta_1$  interventions should be prioritize reducing contact rates of symptomatic individuals. Numerical simulations showed that the disease free equilibrium (DFE) was less than a unit, therefore second and third booster shot may be necessary to prevent gradual immune decay hence maintaining  $R_0$  below a unit.

### **5.4 Suggestions for further research**

This study has not exhausted all about COVID-19 transmission dynamics. Further studies can be done on COVID-19 vaccine efficacy. The model may be extended to include co-infection between COVID-19 and TB or any other underlying conditions. Further studies can also be done on the effects of partially and fully vaccinated individuals on COVID-19 transmission dynamics. Future work could be done to incorporate waning immunity to study the impact of booster shots, which was beyond the scope of this model.

## REFERENCES

- Adebiyi, A. O. (2016). Mathematical modeling of the population dynamics of tuberculosis. *University of the Western Cape: Cape Town, South Africa*.
- Aldila, D., Khoshnaw, S. H., Safitri, E., Anwar, Y. R., Bakry, A. R., Samiadji, B. M., Anugerah, D. A., Gh, M. F. A., Ayulani, I. D., and Salim, S. N. (2020). A mathematical study on the spread of covid-19 considering social distancing and rapid assessment: The case of jakarta, indonesia. *Chaos, Solitons & Fractals*, 139:110042.
- Algarni, A. D., Hamed, A. B., Hamdi, M., Elmannai, H., and Meshoul, S. (2022). Mathematical covid-19 model with vaccination: A case study in saudi arabia. *PeerJ Computer Science*, 8:e959.
- Alzubaidi, L., Al-Sabaawi, A., Bai, J., Dukhan, A., Alkenani, A. H., Al-Asadi, A., Alwzway, H. A., Manoufali, M., Fadhel, M. A., Albahri, A., et al. (2023). Towards risk-free trustworthy artificial intelligence: Significance and requirements. *International Journal of Intelligent Systems*, 2023(1):4459198.
- Antonini, C., Calandrini, S., Stracci, F., Dario, C., and Bianconi, F. (2020). Mathematical modeling and robustness analysis to unravel covid-19 transmission dynamics: the italy case. *Biology*, 9(11):394.
- Bacaër, N. (2011). Ross (1911). In *A short history of mathematical population dynamics*, pages 65–69. Springer.
- Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector,

- S. A., Roupael, N., Creech, C. B., et al. (2021). Efficacy and safety of the mrna-1273 sars-cov-2 vaccine. *New England journal of medicine*, 384(5):403–416.
- Baloch, S., Baloch, M. A., Zheng, T., and Pei, X. (2020). The coronavirus disease 2019 (covid-19) pandemic. *The Tohoku journal of experimental medicine*, 250(4):271–278.
- Buonomo, B., Della Marca, R., d’Onofrio, A., and Groppi, M. (2022). A behavioural modelling approach to assess the impact of covid-19 vaccine hesitancy. *Journal of theoretical biology*, 534:110973.
- Carpio, C. E., Sarasty, O., Hudson, D., Macharia, A., and Shibia, M. (2021). The demand for a covid-19 vaccine in kenya. *Human vaccines & immunotherapeutics*, 17(10):3463–3471.
- Chae, S. Y., Lee, K., Lee, H. M., Jung, N., Le, Q. A., Mafwele, B. J., Lee, T. H., Kim, D. H., and Lee, J. W. (2020). Estimation of infection rate and predictions of disease spreading based on initial individuals infected with covid-19. *Frontiers in Physics*, 8:311.
- Cohen, J. P., Morrison, P., and Dao, L. (2020). Covid-19 image data collection. *arXiv preprint arXiv:2003.11597*.
- Coustasse, A., Kimble, C., and Maxik, K. (2021). Covid-19 and vaccine hesitancy: a challenge the united states must overcome. *The Journal of ambulatory care management*, 44(1):71–75.
- Diagne, M., Rwezaura, H., Tchoumi, S., and Tchuenche, J. (2021). A mathematical model of covid-19 with vaccination and treatment. *Computational and Mathematical Methods in Medicine*, 2021(1):1250129.
- Diekmann, O., Heesterbeek, J. A. P., and Metz, J. A. J. (1990). On the definition and the computation of the basic reproduction ratio  $r_0$  in models for infectious diseases in heterogeneous populations. *Journal of mathematical biology*, 28:365–382.

- Diekmann, O., Heesterbeek, J. A. P., and Roberts, M. G. (2010). The construction of next-generation matrices for compartmental epidemic models. *Journal of the royal society interface*, 7(47):873–885.
- Dietz, K. (1997). Introduction to mckendrick (1926) applications of mathematics to medical problems. *Breakthroughs in Statistics*, pages 17–57.
- Hall, V., Foulkes, S., Insalata, F., Kirwan, P., Saei, A., Atti, A., Wellington, E., Khawam, J., Munro, K., Cole, M., et al. (2022). Protection against sars-cov-2 after covid-19 vaccination and previous infection. *New England Journal of Medicine*, 386(13):1207–1220.
- Ismail, H., Debbouche, A., Hariharan, S., Shangerganesh, L., and Kashtanova, S. V. (2024). Stability and optimality criteria for an svir epidemic model with numerical simulation. *Mathematics*, 12(20):3231.
- Jayaweera, M., Perera, H., Gunawardana, B., and Manatunge, J. (2020). Transmission of covid-19 virus by droplets and aerosols: A critical review on the unresolved dichotomy. *Environmental research*, 188:109819.
- Kermack, W. O. and McKendrick, A. G. (1927). A contribution to the mathematical theory of epidemics. *Proceedings of the royal society of london. Series A, Containing papers of a mathematical and physical character*, 115(772):700–721.
- Lemaitre, J. C., Perez-Saez, J., Azman, A. S., Rinaldo, A., and Fellay, J. (2020). Assessing the impact of non-pharmaceutical interventions on sars-cov-2 transmission in switzerland. *medRxiv*, pages 2020–05.
- Li, Q., Tang, B., Bragazzi, N. L., Xiao, Y., and Wu, J. (2020). Modeling the impact of mass influenza vaccination and public health interventions on covid-19 epidemics with limited detection capability. *Mathematical biosciences*, 325:108378.

- Martcheva, M. (2015). *An introduction to mathematical epidemiology*, volume 61. Springer.
- McCloskey, B. and Heymann, D. L. (2020). Sars to novel coronavirus—old lessons and new lessons. *Epidemiology & Infection*, 148:e22.
- Muchiri, S. K., Muthee, R., Kiarie, H., Sitienei, J., Agweyu, A., Atkinson, P. M., Utazi, C. E., Tatem, A. J., and Alegana, V. A. (2022). Unmet need for covid-19 vaccination coverage in kenya. *Vaccine*, 40(13):2011–2019.
- Musa, S. S., Tariq, A., Yuan, L., Haozhen, W., and He, D. (2022). Infection fatality rate and infection attack rate of covid-19 in south american countries. *Infectious diseases of poverty*, 11(02):42–52.
- Prieto Curiel, R. and González Ramírez, H. (2021). Vaccination strategies against covid-19 and the diffusion of anti-vaccination views. *Scientific Reports*, 11(1):6626.
- Shattock, A. J., Le Rutte, E. A., Dünner, R. P., Sen, S., Kelly, S. L., Chitnis, N., and Penny, M. A. (2022). Impact of vaccination and non-pharmaceutical interventions on sars-cov-2 dynamics in switzerland. *Epidemics*, 38:100535.
- Shen, M., Peng, Z., Xiao, Y., and Zhang, L. (2020). Modeling the epidemic trend of the 2019 novel coronavirus outbreak in china. *The Innovation*, 1(3).
- Sigfrid, L., Drake, T. M., Pauley, E., Jesudason, E. C., Oliaro, P., Lim, W. S., Gillesen, A., Berry, C., Lowe, D. J., McPeake, J., et al. (2021). Long covid in adults discharged from uk hospitals after covid-19: A prospective, multicentre cohort study using the isaric who clinical characterisation protocol. *The Lancet Regional Health—Europe*, 8.
- Sonani, B., Bansal, P., Cusick, A., and Goyal, A. (2020). Impact of covid-19 on healthcare workers. *International Journal of Clinical Case Reports and Reviews*, 3(3).
- Starr, T. N., Greaney, A. J., Addetia, A., Hannon, W. W., Choudhary, M. C., Dingens, A. S.,

Li, J. Z., and Bloom, J. D. (2021). Prospective mapping of viral mutations that escape antibodies used to treat covid-19. *Science*, 371(6531):850–854.

Thompson, S. (2007). Delay-differential equations. *Scholarpedia*, 2(3):2367.

Wangari, I. M., Sewe, S., Kimathi, G., Wainaina, M., Kitetu, V., and Kaluki, W. (2021). Mathematical modelling of covid-19 transmission in kenya: A model with reinfection transmission mechanism. *Computational and Mathematical Methods in Medicine*, 2021(1):5384481.

Xu, S., Liu, P., Mei, S., Lv, Q., Cheng, C., Lu, Y., Kong, D., Wu, X., Wen, Y., Cao, B., et al. (2021). Analysis of the comprehensive non-pharmaceutical interventions and measures in containing the covid-19 epidemic in shenzhen: a retrospective study. *BMJ open*, 11(7):e044940.

## APPENDICES

### APPENDIX I : MATLAB Code: Dynamics of COVID-19 against time

```
% MATLAB script to plot SVAIR model data with smooth curves

% Time points (in days)
time = [0 50 100 150 200 250 300 350 400];

% Data from the table
susceptible = [1 0.96 0.78 0.38 0.25 0.2 0.2 0.19 0.19];
vaccinated = [0 750400 960500 1183400 2290800 4733800 8913700 16130700 17327200];
infectious = [0 270 2720 40590 53475 45250 5900 1100 450];
recovery = [0 0.1 0.48 0.75 0.82 0.85 0.87 0.9 0.9];

% Generate smooth time points
smooth_time = linspace(min(time), max(time), 200);

% Interpolate using spline for smooth curves
smooth_susceptible = interp1(time, susceptible,
smooth_time, 'spline');
smooth_vaccinated = interp1(time, vaccinated,
smooth_time, 'spline');
smooth_infectious = interp1(time, infectious,
smooth_time, 'spline');
smooth_recovery = interp1(time, recovery, smooth_time, 'spline');

% Plot Susceptible Population
figure;
plot(smooth_time, smooth_susceptible, 'b', 'LineWidth', 2);
xlabel('Time (days)');
ylabel('Susceptible Percentage');
```

```

        title('Susceptible Population');
grid on;

% Plot Vaccinated Population
figure;
plot(smooth_time, smooth_vaccinated, '- ', 'LineWidth', 2);
xlabel('Time (days)');
ylabel('Cumulative Vaccinated');
title('Vaccinated Population');
grid on;
ylim([0 max(vaccinated)]); % Ensure axis starts at 0

% Plot Infectious Population
figure;
plot(smooth_time, smooth_infectious, '- ', 'LineWidth', 2);
xlabel('Time (days)');
ylabel('Infectious Cases');
title('Infectious Population');
grid on;

% Plot Recovery Population
figure;
plot(smooth_time, smooth_recovery, '- ', 'LineWidth', 2);
xlabel('Time (days)');
ylabel('Recovery Percentage');
title('Recovery Population');
grid on;
ylim([0 max(recovery)]); % Ensure axis starts at 0

```

## APPENDIX II : MATLAB Code: $R_0$ variations with different model parameters

% MATLAB script to plot  $R_0$  variations with different parameters separately (without circles)

% (a)  $R_0$  vs Death rate due to COVID-19 ( $\hat{I}^{1/4}$ )

mu = [0.6248 0.5 0.4 0.3 0.2 0.1] \*  $10^{-3}$ ;

R0\_mu = [0.4054 0.3559 0.3067 0.2494 0.1815 0.1];

figure;

plot(mu, R0\_mu, '-','LineWidth', 2);

xlabel('mu (Death rate due to COVID-19)');

ylabel('R\_0');

title('R\_0 vs mu');

grid on;

% (b)  $R_0$  vs Natural death rate ( $\hat{I}^3$ )

gamma = [0.0107 0.02 0.03 0.04 0.05 0.06];

R0\_gamma = [0.5994 0.4537 0.3325 0.23 0.1425 0.06942];

figure;

plot(gamma, R0\_gamma, '-','LineWidth', 2);

xlabel('gamma (Natural death rate)');

ylabel('R\_0');

title('R\_0 vs gamma');

grid on;

% (c)  $R_0$  vs Recovery rate of Infectious ( $\hat{I}^{\pm}$ )

alpha = [0.1 0.2 0.3 0.4 0.5 0.6];

R0\_alpha = [0.6488 1.425 2.3 3.325 4.537 5.9945];

figure;

plot(alpha, R0\_alpha, '-','LineWidth', 2);

xlabel('alpha (Recovery rate of Infectious)');

```

ylabel('R_0');
title('R_0 vs alpha');
grid on;
% (d) R0 vs Rate of progression from A to I ( $\hat{I}$ )
delta = [0.1428 0.12 0.1 0.08 0.06 0.04];
R0_delta = [0.9265 0.8547 0.7669 0.665 0.5445 0.3996];
figure;
plot(delta, R0_delta, '-','LineWidth', 2);
xlabel('delta (Progression from A to I)');
ylabel('R_0');
title('R_0 vs delta');
grid on;
% (e) R0 vs Time delay ( $\hat{I}_{,,}$ )
tau = [7 8.3 10.0 12.5 16.67 25];
R0_tau = [0.9265 0.8547 0.7669 0.665 0.5445 0.3996];
figure;
plot(tau, R0_tau, '-','LineWidth', 2);
xlabel('tau (Time delay)');
ylabel('R_0');
title('R_0 vs tau');
grid on;
ylim([0 1]);

```

### **APPENDIX III : Clearance to commence field work**



UNIVERSITY OF KABIANGA  
ISO 9001:2015 CERTIFIED

OFFICE OF THE DIRECTOR, BOARD OF GRADUATE STUDIES

REF: PGC/AM/001/20

DATE: 6<sup>TH</sup> MARCH, 2024

Peter Kibii Cheruiyot,  
Mathematics, Actuarial and Physical Sciences Department,  
University of Kabianga,  
P.O Box 2030- 20200,  
KERICHO.

Dear Mr. Cheruiyot,

**RE: CLEARANCE TO COMMENCE FIELD WORK/DATA COLLECTION**

I am pleased to inform you that the Board of Graduate Studies has considered and approved your MSc research proposal entitled "**Modelling the Effects of Vaccination, Incubation and Treatment on COVID – 19 Transmission Dynamics.**"

Subsequently the Board has also approved the following supervisors for appointments.

1. Dr. Wesley Kirui
2. Dr. Reuben Langat
3. Dr. Benard Tonui

You may now proceed to commence field work/data collection on condition that you obtain a research permit from NACOSTI and /or an ethical review permit from a relevant ethics review board.

You are also required to publish one (1) article in a peer reviewed journal, with all your supervisors, before your oral defense of thesis.

You are required to submit through your supervisors, and HoD, progress reports every three months, to the Director, Board of Graduate Studies.

Please note that it is the policy of the University that you complete your studies within three years from the date of registration. Do not hesitate to consult this office in case of any difficulties encountered in the course of your studies.

I wish you all the best in your research and hope that your study will yield original contribution for the betterment of humanity.

Yours Sincerely,



Dr. Ronald K. Rop

DIRECTOR, BOARD OF GRADUATE STUDIES.

RKR/lc

- cc
1. Dean, SST
  2. HOD, MAPS
  3. Supervisors

## **APPENDIX V : NACOSTI Research Permit**



REPUBLIC OF KENYA



NATIONAL COMMISSION FOR  
SCIENCE, TECHNOLOGY & INNOVATION

Ref No: 408657

Date of Issue: 06/March/2025

## RESEARCH LICENSE



This is to Certify that Mr.. PETER KIBII CHERUIYOT of University of Kabianga, has been licensed to conduct research as per the provision of the Science, Technology and Innovation Act, 2013 (Rev.2014) in Bomet on the topic: MODELLING THE EFFECTS OF VACCINATION, INCUBATION AND TREATMENT ON COVID -19 TRANSMISSION DYNAMICS for the period ending : 06/March/2026.

License No: NACOSTI/P/25/415936

408657

Applicant Identification Number

Director General  
NATIONAL COMMISSION FOR  
SCIENCE, TECHNOLOGY &  
INNOVATION

Verification QR Code



NOTE: This is a computer generated License. To verify the authenticity of this document,  
Scan the QR Code using QR scanner application.

See overleaf for conditions

**THE SCIENCE, TECHNOLOGY AND INNOVATION ACT, 2013 (Rev. 2014)**  
Legal Notice No. 108: The Science, Technology and Innovation (Research Licensing) Regulations, 2014

The National Commission for Science, Technology and Innovation, hereafter referred to as the Commission, was established under the Science, Technology and Innovation Act 2013 (Revised 2014) herein after referred to as the Act. The objective of the Commission shall be to regulate and assure quality in the science, technology and innovation sector and advise the Government in matters related thereto.

**CONDITIONS OF THE RESEARCH LICENSE**

1. The License is granted subject to provisions of the Constitution of Kenya, the Science, Technology and Innovation Act, and other relevant laws, policies and regulations. Accordingly, the licensee shall adhere to such procedures, standards, code of ethics and guidelines as may be prescribed by regulations made under the Act, or prescribed by provisions of International treaties of which Kenya is a signatory to.
2. The research and its related activities as well as outcomes shall be beneficial to the country and shall not in any way;
  - i. Endanger national security
  - ii. Adversely affect the lives of Kenyans
  - iii. Be in contravention of Kenya's international obligations including Biological Weapons Convention (BWC), Comprehensive Nuclear-Test-Ban Treaty Organization (CTBTO), Chemical, Biological, Radiological and Nuclear (CBRN).
  - iv. Result in exploitation of intellectual property rights of communities in Kenya
  - v. Adversely affect the environment
  - vi. Adversely affect the rights of communities
  - vii. Endanger public safety and national cohesion
  - viii. Plagiarize someone else's work
3. The License is valid for the proposed research, location and specified period.
4. Neither the license nor any rights thereunder are transferable.
5. The Commission reserves the right to cancel the research at any time during the research period if in the opinion of the Commission the research is not implemented in conformity with the provisions of the Act or any other written law.
6. The Licensee shall inform the relevant County Director of Education, County Commissioner and County Governor before commencement of the research.
7. Excavation, filming, movement, and collection of specimens are subject to further necessary clearance from relevant Government Agencies.
8. The License does not give authority to transfer research materials.
9. The Commission may monitor and evaluate the licensed research project for the purpose of assessing and evaluating compliance with the conditions of the License.
10. The Licensee shall submit one hard copy, and upload a soft copy of their final report (thesis) onto a platform designated by the Commission within one year of completion of the research.
11. The Commission reserves the right to modify the conditions of the License including cancellation without prior notice.
12. Research, findings and information regarding research systems shall be stored or disseminated, utilized or applied in such a manner as may be prescribed by the Commission from time to time.
13. The Licensee shall disclose to the Commission, the relevant Institutional Scientific and Ethical Review Committee, and the relevant national agencies any inventions and discoveries that are of National strategic importance.
14. The Commission shall have powers to acquire from any person the right in, or to, any scientific innovation, invention or patent of strategic importance to the country.
15. Relevant Institutional Scientific and Ethical Review Committee shall monitor and evaluate the research periodically, and make a report of its findings to the Commission for necessary action.

National Commission for Science, Technology and  
Innovation (NACOSTI),  
Off Waiyaki Way, Upper Kabete,  
P. O. Box 30623 - 00100 Nairobi, KENYA  
Telephone: 020 4007000, 0713788787, 0735404245  
E-mail: dg@nacosti.go.ke  
Website: www.nacosti.go.ke

## **APPENDIX VI : Publication from the Thesis**



# Modelling the Effects of Vaccination and Incubation on Covid-19 Transmission Dynamics

Cheruiyot Kibii Peter <sup>a\*</sup>, Kirui Wesley <sup>b</sup>, Langat Reuben <sup>a</sup>  
and Tonui Benard <sup>a</sup>

<sup>a</sup> Department of Mathematics, Actuarial and Physical Sciences, University of Kabianga, Kenya.

<sup>b</sup> Department of Mathematics and Actuarial Science, South Eastern Kenya University, Kenya.

## Authors' contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

## Article Information

DOI: <https://doi.org/10.9734/jamcs/2025/v40i72017>

## Open Peer Review History:

This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: <https://pr.sdiarticle5.com/review-history/137911>

Original Research Article

Received: 08/04/2025

Accepted: 10/06/2025

Published: 16/06/2025

## Abstract

The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) is a strain of Coronavirus that causes Coronavirus Disease 2019 (COVID-19). The respiratory illness responsible for the COVID19 pandemic began in December 2019 in Wuhan city, China. Mathematical modeling has enabled the epidemiologist to understand the dynamics of the disease, its impact and future predictions in order to provide the governments with the best policies and strategies to curb the spread of the virus. Deterministic susceptible-vaccinated-asymptomatic-infectious-recovered (SVAIR) model was formulated incorporated with time delay. The delay accounts for the time lapsed between exposure and infectious period. Furthermore, time delay and vaccination inversely affects

\*Corresponding author: Email: [kibii2012@gmail.com](mailto:kibii2012@gmail.com);

the basic reproduction number hence play a major role in stabilizing the rate of infection. In this study delay differential equations (DDE) were formulated for the purposes of determining the stability of both disease free equilibrium (DFE) and endemic equilibrium point (EEP). It was found out that the model was stable at both Disease Free Equilibrium (DFE) and Endemic Equilibrium Point (EEP) and was attained whenever  $R_0 < 1$  and  $R_0 > 1$  respectively. Calculations based on secondary data from various works of literature and the WHO dashboard was used. The basic reproduction number ( $R_0$ ) was computed using the next generation matrix (NGM) approach. Finally, numerical simulations were carried out using MATLAB for validation of the analytical results. Graphical representation shows that stability is achieved when  $\tau > 5$  days and that  $R_0 = 0.95$  at DFE. Furthermore at EEP it was noted that  $R_0 = 1.02$  hence stability was guaranteed.

**Keywords:** COVID-19; reproduction number; delay differential equations; stability; disease free equilibrium.

## 1 Introduction

The devastating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) is a strain of Coronavirus that causes Coronavirus Disease 2019 (COVID-19). The respiratory illness responsible for the COVID-19 pandemic which began in December 2019 (WHO, 2020) in Wuhan City, China and spread to many countries in the world (Shen et al., 2020). Kenya reported its first case of COVID-19 in March 2020. This resulted in the restriction of movement by the government, which included the closure of all learning institutions (McCloskey et al., 2020).

As of 18<sup>th</sup> April 2022, COVID-19 had spread to every country in the world, resulting in 500,186,525 confirmed cases of infection and 6,190,349 deaths globally, according to the WHO's pandemic declaration from March 2020 (WHO, 2020). The number of COVID-19 cases reported to WHO by selected countries as at April 2022 include; USA had 79,716,960 confirmed cases and 2,711,776 deaths, United Kingdom had reported 21,715,120 confirmed cases and 979,321 deaths, Africa had reported cumulative of 8,676,141 confirmed cases and 171,350 deaths and Kenya had reported 323,588 confirmed cases and 5649 deaths, (Shen et al., 2020).

Over time, it became evident that the Kenyan government's non-pharmaceutical mitigation measures to curb the spread of COVID-19 were not effective. Use of face masks, keeping of social distance, routine hand washing, isolation of suspected cases and contact tracing were a few examples of such intervention measures. Because of the rapid spread of COVID-19 globally, vaccination has been identified as the best containment strategy by several countries. The WHO approved COVID-19 vaccines where Kenya used different types of vaccines such as Astra Zeneca, Modena, Pfizer and Johnson and Johnson. In this study, an SVAIR mathematical model was formulated using delay differential equations (DDE) in which delay is incorporated to ascertain for the incubation period in the COVID-19 transmission dynamics.

## 2 Review of Related Literature

The novel coronavirus identified as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) is a strain of Coronavirus that causes Coronavirus Disease 2019. This disease was named by the World Health Organization (WHO) as Coronavirus Disease 2019 (COVID-19) (WHO, 2020). WHO declared COVID-19 a pandemic in March 2020.

Musa et al., (2022), studied the infection fatality rate and infection rate of COVID-19 in Nigeria using a susceptible-exposed-infectious-recovered (SEIR) based model with a time-varying transmission rate controlled by systems of delayed differential equations (DDEs). They discovered that the awareness campaigns, in particular the use of non-pharmaceutical measures in mitigating the spread of COVID-19 were effective during the earliest period of infection.

Xu et al., 2021, in their study found out that in the absence of vaccines, early detection, isolation and treatment were then the most efficient intervention measures. The study only concentrated on non-pharmaceutical approaches for containing and lessening the pandemic impact in the absence of reliable vaccines or antivirals. These mitigation measures were temporary, since over time, the general populace has a tendency to loosen them, which would accelerate the spread of COVID-19. This study did not consider how the COVID-19 incubation period affected the isolated and confined patients.

Wangari et al., (2021), studied the mathematical modeling of COVID-19 transmission in Kenya, a model with a re-infection transmission mechanism. They found out that a large pool of infectious people who were asymptomatic would eventually increase symptomatic people with mild and severe symptoms, which may eventually increase the overall number of reported deaths. The model used deterministic ordinary differential equations (ODEs) for computation of basic reproduction number. Unfortunately, the model did not take into account the incubation period during asymptomatic period but it called for further research on the problems presented by asymptomatic patients in connection with reinfection.

Aldila et al., (2020), in their study, they considered the undiscovered asymptomatic individuals who actively contributed to the transmission of COVID-19 despite having no symptoms. The study also demonstrated that the inadequate healthcare resources contributed to the spread of COVID-19 virus. SVEIAHR mathematical model were developed, sensitivity analysis was used to determine how the model parameters affected the spread of the disease. The study found out that although it was necessary to reduce the basic reproductive number below one in order to stop the spread of infection, it was not sufficient because several additional intervention measures were required.

Lemaitre et al., (2020), in their study, they investigated the effects of non-pharmaceutical strategies, according to their studies, there was a significant amount of virus transmission through contaminated surfaces, depending on the nature of the virus. This study expressed concern over the fact that public awareness of COVID-19 was one of the major challenge in curbing the spread of COVID-19. Many people choose not to follow the safety precautions already in place including wearing face masks, regularly sanitizing, avoiding crowded areas and maintaining social distance. The mathematical model did not considered vaccination as the mitigation measure against the spread of COVID-19.

Shattock et al., (2022), studied the mathematical model based on ordinary differential equations (ODEs). Their study subdivided the total population into; susceptible, vaccinated, infectious, asymptomatic and recovered (SVIAR). Their study showed that vaccinations could assist to reduce transmission rates, but they also stated that during the COVID-19 pandemic, proper waste management was essential. In addition, it did not state how the asymptomatic individuals affect the transmission dynamic of COVID-19 and the time delay.

The above studies did not consider the use of delay differential equations (DDEs) in modeling the transmission dynamics of COVID-19. This study formulated a mathematical model incorporating DDEs for the transmission dynamics of COVID-19 in Kenya in which incubation period is considered.

## 3 Methodology

### 3.1 Introduction

In epidemiology, the basic reproduction number of an infection is the mean number of new infections arising from a single infectious person introduced into a purely susceptible population during infectious period. The basic reproduction number  $R_0$  is the threshold for many epidemiological models. When  $R_0 > 1$  the disease-free equilibrium point is unstable, the infection will be able to spread in a population and locally stable for  $R_0 < 1$ , the infection dies out in the long run.

To obtain  $R_0$  the dominant eigenvalue of the next generation matrix is considered such that  $R_0 = \rho FV^{-1}$ . Where  $\rho$  is the spectral radius of the next generation matrix. Matrix  $F_i$  represents the rate of new infection entering compartment  $i$ , and matrix  $V_i$  represents the rate of transfer into and out of compartment  $i$  by other means. Since we are dealing with large population, compartmental mathematical model is used. The total population is subdivided into compartments each representing a specific stage of epidemic. The Susceptible-Vaccinated-Asymptomatic- Infected- Recovered (SVAIR) mathematical models are utilized to study and analyze the COVID-19 transmission dynamics.

### 3.2 Methods of solution

The stability of the model has been determined using the Jacobian matrix which is a system of partial derivative of equations for checking the stability of Disease Free Equilibrium (DFE) and numerical simulation was done using MATLAB to validate the analytic results.




Fig. 1. SVAIR model flow diagram

### 3.3 Model equations

$$\left. \begin{aligned} \frac{dS(t)}{dt} &= p - \omega S - \beta_1 S I_\tau - \beta_2 S I_\tau - \gamma_1 S \\ \frac{dV(t)}{dt} &= \omega S - \varepsilon_1 V_\tau I_\tau - \varepsilon_2 V_\tau I_\tau - \varepsilon_3 V_\tau I_\tau - \gamma_2 V \\ \frac{dA(t)}{dt} &= \beta_2 S I_\tau + \varepsilon_2 V_\tau I_\tau - \delta_1 A_\tau - \delta_2 A_\tau - \gamma_3 A \\ \frac{dI(t)}{dt} &= \beta_1 S I_\tau + \varepsilon_1 V_\tau I_\tau + \delta_1 A_\tau - \alpha I_\tau - (\gamma_4 + \mu) I \\ \frac{dR(t)}{dt} &= \alpha I_\tau + \delta_2 A_\tau + \varepsilon_3 V_\tau I_\tau - \gamma_5 R \end{aligned} \right\} \quad (3.1)$$

### 3.4 Model preliminary analysis

#### 3.4.1 Positivity and boundedness of the model

Positivity and boundedness of the model is shown before doing result analysis for model equation 3.1 to be epidemiologically meaningful. Thus, we show that all state variables of the model equation (3.1) are nonnegative for all time  $t > 0$  and bounded and the existence of solutions are underscored by these properties.

Let  $C = C[-\tau, 0], \mathfrak{R}^5$  be a Banach space of continuous functions mapping the interval  $[-\tau, 0]$  into  $\mathfrak{R}^5$  with the topology of uniform convergence. By fundamental theory of differential equations, it can be shown that there exists a unique solution  $(S(t), V(t), A(t), I(t), R(t))$  of the model equation 3.1 with initial data.

$$(S(0) > 0, V(0) > 0, A(0) > 0, I(0) > 0, R(0) > 0 \in C) \quad (3.2)$$

In addition, we assume that the initial data for the model equation 3.2 satisfies;

$$S_0(p) \geq 0, V_0(p) \geq 0, A_0(p) \geq 0, I_0(p) \geq 0, R_0(p) \geq 0, \in [-\tau, 0] \quad (3.3)$$

The following theorem establishes the positivity and boundedness of the solution with initial functions satisfying (3.2) and (3.3)

### Theorem 3.1

Let (SVAIR) be the solution of the model equation 3.1 satisfying the condition 3.2 and 3.3. then S,V,A,I and R are all positive and bounded for all  $t > 0$  at which the solution exist.

### Proof

From the equation 3.1 we have

$$S(t) = S(0)e^{-\int_0^t (\omega + \beta_1 I_\tau + \beta_2 I_\tau + \gamma_1) d\theta} + \int_0^t (p + (\omega + \beta_1 I_\tau + \beta_2 I_\tau + \gamma_1)) S(\varphi) e^{\int_0^t (\omega + \beta_1 I_\tau + \beta_2 I_\tau + \gamma_1) d\theta} d\varphi \quad (3.4)$$

From 3.4 it is clearly seen that  $S(t) > 0$  hence positive. Similarly, it can be shown that

$$V(t) > 0, A(t) > 0, I(t) > 0, R(t) > 0 \quad (3.5)$$

Using equation 3.2 and 3.3, positivity follows immediately from the above integral forms.

For boundedness we define

$$N(t) = S(t) + V(t) + A(t) + I(t) + R(t) \quad (3.6)$$

$$\frac{dN(t)}{dt} = \frac{d(S(t) + V(t) + A(t) + I(t) + R(t))}{dt} \quad (3.7)$$

$$\frac{dN(t)}{dt} = p - \gamma(S(t) + V(t) + A(t) + I(t) + R(t)) \quad (3.8)$$

$$\text{Thus } \frac{dN(t)}{dt} \leq p - \Sigma \quad (3.9)$$

$$\text{Where } \Sigma = \gamma S + \gamma V + \gamma A + \gamma I + \gamma R \quad (3.10)$$

This implies that  $N(t)$  is bounded and so are

$S(t) + V(t) + A(t) + I(t) + R(t)$ . This complete the proof of theorem 3.1

### 3.4.2 Computation of basic reproduction number $R_0$

Infections produced by a single infectious individual during the course of their infectious period are known as the basic reproduction number.  $R_0$  is the threshold value for infectious disease models because when  $R_0 < 1$ , the disease dies off, indicating that the disease free equilibrium state (DFE) is stable and when  $R_0 > 1$ , the DFE is unstable, meaning that the disease spread throughout the population.

In this study we adopted the next generation matrix (NGM) approach in computation of  $R_0$  such that  $R_0 = \rho FV^{-1}$  where  $\rho$  is the spectral radius for NGM while  $F$  is the matrix of new infection by the disease and  $V$  is the matrix of transfer of infection in and out of the compartment by other means. The dominant eigenvalue of the NGM is considered as  $R_0$ . In the model equation 3.1, there are two infectious classes; A and I hence at disease free equilibrium, the matrix of new infection is given by matrix F and V.

Matrix  $F_i$  is obtained by considering the rate of new infections entering the compartment  $i$  is given by;

$$F_i = \begin{bmatrix} \beta_2 S I_\tau + \varepsilon_2 V_\tau I_\tau \\ \beta_1 S I_\tau + \varepsilon_1 V_\tau I_\tau + \delta_1 A_\tau \end{bmatrix} \quad (3.11)$$

The matrix that represents the rate of transfer into and out of compartment by other means at DFE is given by;

$$V_i = \begin{bmatrix} \delta_1 A_\tau + \delta_2 A_\tau + \gamma_3 A \\ \alpha I_\tau + (\gamma_4 + \mu) I \end{bmatrix} \quad (3.12)$$

We then differentiate  $F_i$  partially with respect to the state variables to obtain a  $2 \times 2$  matrix

$$F_i = \begin{bmatrix} 0 & (\varepsilon_2 V_\tau + \beta_2 S) e^{-\lambda_\tau} \\ \delta_1 e^{-\lambda_\tau} & (\varepsilon_1 V_\tau + \beta_1 S) e^{-\lambda_\tau} \end{bmatrix} \quad (3.13)$$

Similarly, differentiating matrix  $V_i$  partially with respect to the state variables, we obtain a  $2 \times 2$  matrix,

$$V_i = \begin{bmatrix} (\delta_1 + \delta_2) e^{-\lambda_\tau} + \gamma_3 & 0 \\ 0 & \alpha e^{-\lambda_\tau} + (\gamma_4 + \mu) \end{bmatrix} \quad (3.14)$$

The inverse of V is computed as

$$V^{-1} = \begin{bmatrix} \frac{1}{(\delta_1 + \delta_2) e^{-\lambda_\tau} + \gamma_3} & 0 \\ 0 & \frac{1}{\alpha e^{-\lambda_\tau} + (\gamma_4 + \mu)} \end{bmatrix} \quad (3.15)$$

Using the next generation matrix (NGM) to determine the basic reproduction number  $R_0$

$$NGM = FV^{-1} = \begin{bmatrix} 0 & \frac{(\varepsilon_2 V_\tau + \beta_2 S) e^{-\lambda_\tau}}{\alpha e^{-\lambda_\tau} + (\gamma_4 + \mu)} \\ \frac{\delta_1 e^{-\lambda_\tau}}{(\delta_1 + \delta_2) e^{-\lambda_\tau} + \gamma_3} & \frac{(\varepsilon_1 V_\tau + \beta_1 S) e^{-\lambda_\tau}}{\alpha e^{-\lambda_\tau} + (\gamma_4 + \mu)} \end{bmatrix} \quad (3.16)$$

The eigenvalues of matrix (3.16) are computed by  $|J - I\lambda| = 0$ , where  $J$  is the matrix  $FV^{-1}$  and  $I$  is  $2 \times 2$  identity matrix.

$$\begin{vmatrix} 0 - \lambda & \frac{(\varepsilon_2 V_\tau + \beta_2 S) e^{-\lambda_\tau}}{\alpha e^{-\lambda_\tau} + (\gamma_4 + \mu)} \\ \frac{\delta_1 e^{-\lambda_\tau}}{(\delta_1 + \delta_2) e^{-\lambda_\tau} + \gamma_3} & \frac{(\varepsilon_1 V_\tau + \beta_1 S) e^{-\lambda_\tau}}{\alpha e^{-\lambda_\tau} + (\gamma_4 + \mu)} - \lambda \end{vmatrix} \quad (3.17)$$

Solving for the eigenvalues we obtain;

$$\left. \begin{aligned} \lambda_{*1} &= 0 \\ \lambda_{*2} &= \frac{(\varepsilon_1 V_\tau + \beta_1 S) e^{-\lambda_\tau}}{\alpha e^{-\lambda_\tau} + (\gamma_4 + \mu)} \end{aligned} \right\} \quad (3.18)$$

The dominant eigenvalue is;

$$\lambda_{*2} = \frac{(\varepsilon_1 V_\tau + \beta_1 S) e^{-\lambda_\tau}}{\alpha e^{-\lambda_\tau} + (\gamma_4 + \mu)} \quad (3.19)$$

$$\text{Therefore, } R_0 \text{ (model 3.1)} = \lambda_{*2} = \frac{(\varepsilon_1 V_\tau + \beta_1 S) e^{-\lambda_\tau}}{\alpha e^{-\lambda_\tau} + (\gamma_4 + \mu)} \quad (3.20)$$

### 3.5 Local stability of disease free equilibrium

Mathematical epidemiology considers two equilibria points; Disease Free Equilibrium Point (DFE) where  $R_0 < 1$  and Endemic Equilibrium Point (EEP) where  $R_0 > 1$ . DFE occurs in absence of the disease while EEP occurs

in presence of a disease. A system is stable if all the eigenvalues of the linearized matrix about a fixed point have negative real parts. The dominant eigenvalue of the Jacobian matrix obtained during disease DFE yield the basic reproduction number  $R_0$  which determine the stability of the disease. DFE is an equilibrium point described when the rate of change is equal to zero. It is evaluated by equating the system of delay differential equations (3.1) to zero. The Jacobian matrix is obtained from the first partial derivative of the model equations 3.1 in which the DFE is locally asymptotically stable if  $R_0 < 1$ , otherwise unstable. To obtain the Jacobian matrix we differentiate equation (3.1) with respect to state variables at DFE.

$$\left. \begin{aligned} p - \omega S - \beta_1 S I_\tau - \beta_2 S I_\tau - \gamma_1 S &= 0 \\ \omega S - \varepsilon_1 V_\tau I_\tau - \varepsilon_2 V_\tau I_\tau - \varepsilon_3 V_\tau I_\tau - \gamma_2 V &= 0 \\ \beta_2 S I_\tau + \varepsilon_2 V_\tau I_\tau - \delta_1 A_\tau - \delta_2 A_\tau - \gamma_3 A &= 0 \\ \beta_1 S I_\tau + \varepsilon_1 V_\tau I_\tau + \delta_1 A_\tau - \alpha I_\tau - (\gamma_4 + \mu) I &= 0 \\ \alpha I_\tau + \delta_2 A_\tau + \varepsilon_3 V_\tau I_\tau - \gamma_5 R &= 0 \end{aligned} \right\} \quad (3.21)$$

The linearization matrix is given by;

$$\begin{bmatrix} -(\omega + \beta_1 I_\tau + \beta_2 I_\tau + \gamma_1) & 0 & 0 & 0 & 0 \\ \omega & -(\varepsilon_1 + \varepsilon_2 + \varepsilon_3) I_\tau e^{-\lambda_\tau} - \gamma_2 & 0 & -(\varepsilon_1 + \varepsilon_2 + \varepsilon_3) v_\tau e^{-\lambda_\tau} & 0 \\ \beta_2 I_\tau & \varepsilon_2 I_\tau e^{-\lambda_\tau} & -(\delta_1 + \delta_2) e^{-\lambda_\tau} - \gamma_3 & (\beta_2 S + \varepsilon_2 V_\tau) e^{-\lambda_\tau} & 0 \\ \beta_1 I_\tau & \varepsilon_1 I_\tau e^{-\lambda_\tau} & \delta_1 e^{-\lambda_\tau} & -(\alpha - \beta_1 S - \varepsilon_1 v_\tau) e^{-\lambda_\tau} - (\gamma_4 + \mu) & 0 \\ 0 & \varepsilon_3 I_\tau e^{-\lambda_\tau} & \delta_2 e^{-\lambda_\tau} & (\alpha + \varepsilon_3 v_\tau) e^{-\lambda_\tau} & -\gamma_5 \end{bmatrix} \quad (3.22)$$

The equation 3.1 is locally asymptotically stable if all the eigenvalues of the linearization matrix of the equation 3.1 are negative. The eigenvalues are:

$$\begin{aligned} \lambda_{**1} &= -(\omega + \beta_1 I_\tau + \beta_2 I_\tau + \gamma_1) \\ \lambda_{**2} &= -(\varepsilon_1 + \varepsilon_2 + \varepsilon_3) I_\tau e^{-\lambda_\tau} - \gamma_2 \\ \lambda_{**3} &= -(\delta_1 + \delta_2) e^{-\lambda_\tau} - \gamma_3 \\ \lambda_{**4} &= -(\alpha - \beta_1 S - \varepsilon_1 v_\tau) e^{-\lambda_\tau} - (\gamma_4 + \mu) \\ \lambda_{**5} &= -\gamma_5 \end{aligned} \quad (3.23)$$

For the model 3.1, it is clear that the dominant eigenvalue is;

$$\lambda_{**4} = -(\alpha - \beta_1 S - \varepsilon_1 v_\tau) e^{-\lambda_\tau} - (\gamma_4 + \mu) \quad (3.24)$$

### Theorem 3.2

Disease free equilibrium is stable whenever  $R_0 < 1$ , otherwise it's unstable.

### Proof

$\lambda_{**4}$  should be negative. This can only be negative if,

$$-(\alpha - \beta_1 S - \varepsilon_1 v_\tau) e^{-\lambda_\tau} - (\gamma_4 + \mu) = 0$$

Which simplifies to

$$(\beta_1 S + \varepsilon_1 v_\tau) e^{-\lambda_\tau} < \alpha e^{-\lambda_\tau} + (\gamma_4 + \mu) \quad (3.25)$$

This implies that;

$$R_0 = \frac{(\beta_1 S + \varepsilon_1 v_\tau) e^{-\lambda_\tau}}{\alpha e^{-\lambda_\tau} + (\gamma_4 + \mu)} < 1 \quad (3.26)$$

Therefore  $R_0 < 1$  is obtained for DFE to be stable.

## 4 Numerical Analysis and Results

This section comprises of parameter values obtained from literature and graphs obtained using Matlab. (Table 4.1)

**Table 1. Table of parameters, parameter description, values and source**


| Parameter                 | Description                                            | Value                                    | Source                                |
|---------------------------|--------------------------------------------------------|------------------------------------------|---------------------------------------|
| $S$                       | Susceptible class                                      | $5.036 \times 10^7 \text{ years}^{-1}$   | Estimated from (Muchiri et al., 2022) |
| $V$                       | Coronavirus disease vaccinated class                   | 0                                        | (Carpio et al., 2021)                 |
| $A$                       | Asymptomatic infected class                            | $7322 \text{ years}^{-1}$                | (Carpio et al., 2021)                 |
| $I$                       | Symptomatic infected class                             | $7545 \text{ years}^{-1}$                | Estimated from (Muchiri et al., 2022) |
| $R$                       | Recovered class                                        | $203968 \text{ years}^{-1}$              | Estimated from (Muchiri et al., 2022) |
| $p$                       | Recruitment rate                                       | $1762 \text{ days}^{-1}$                 | Estimated from (Muchiri et al., 2022) |
| $\omega$                  | Rate of progression from S to V                        | $0.002 \text{ days}^{-1}$                | Assumed                               |
| $\beta_1$                 | Transition rate from susceptible to infectious class   | $0.233 \text{ days}^{-1}$                | (Chae et al., 2020)                   |
| $\beta_2$                 | Transition rate from susceptible to asymptomatic class | $0.09786 \text{ days}^{-1}$              | (Algarni et al., 2022)                |
| $\varepsilon_1$           | Rate of progression from V to I                        | $0.462 \text{ days}^{-1}$                | Chae et al., 2020                     |
| $\varepsilon_2$           | Rate of progression from V to A                        | $0.039 \text{ days}^{-1}$                | (Li et al., 2020)                     |
| $\frac{1}{\varepsilon_3}$ | Immunity development period                            | $0.0714 \text{ days}^{-1}$               | (Algarni et al., 2022)                |
| $\delta_1$                | Rate of progression from A to I                        | $0.1428 \text{ days}^{-1}$               | (Algarni et al., 2022)                |
| $\delta_2$                | Rate of progress from A to R                           | $0.165 \text{ days}^{-1}$                | (Buonomo et al., 2022)                |
| $\alpha$                  | Rate of progression from I to R                        | $0.1 \text{ days}^{-1}$                  | (Algarni et al., 2022)                |
| $\gamma$                  | Natural death rate                                     | $1.07 \times 10^{-2} \text{ years}^{-1}$ | (Buonomo et al., 2022)                |
| $\mu$                     | Disease induced death rate                             | $6.248 \times 10^{-4} \text{ days}^{-1}$ | (Buonomo et al., 2022)                |
| $\tau$                    | Time delay                                             | To be determined                         |                                       |

Fig. 2 shows the dynamics of population of various compartments against time in days. From the graph, it is evident that nearly the entire population were susceptible from the onset and as the infections number increases, the number of susceptible individual drastically decreases to about 20 percent because vaccination, treatment and time delay played a major role in stabilizing the rate of infection. Increasing vaccination coverage means immunity of the susceptible individual is improved hence the infectious period delayed and therefore the basic reproduction number is lowered, minimizing the rate of infection.


Fig. 3 shows that the reproduction number  $R_0$  is directly proportion to the rate of death due to COVID-19 ( $\mu$ ) unless intervention measures like vaccination is rolled out which increases the latent period hence  $R_0$  is lowered resulting in reduced death rate.

Fig. 4 shows a plot of reproduction number against the rate of progression from asymptomatic (A) to infectious (I). It is evident that  $R_0$  is directly proportional to the rate of progression  $\delta$ . A shorter asymptomatic infectious period potentially increases the value of  $R_0$  hence higher rate of progression from A to I.


Fig. 5 shows a plot of reproduction number against time delay at DFE. From the graph  $R_0$  is inversely proportional to time delay  $\tau$ . A shorter  $\tau$  leads to a higher  $R_0$ , therefore highly contagious variants spread faster before intervention measures can take effect.




**Fig. 2. A plot of SVAIR model population against time**



**Fig. 3. A plot of  $R_0$  against Death rate due to COVID-19 ( $\mu$ )**



**Fig. 4. A plot of  $R_0$  at EEP against Delta ( $\delta$ )**



**Fig. 5. A plot of  $R_0$  against Time delay ( $\tau$ )**

## 5 Conclusion

It was found out that the model was stable at both Disease Free Equilibrium (DFE) and Endemic Equilibrium Point (EEP) and was attained when  $R_0 < 1$  and  $R_0 > 1$  respectively. Parameter values were taken from the literature, and the analytical findings were verified numerically using the Matlab dde 23 solver. This was affected by vaccination, time delay and the rate of progression from asymptomatic class to infectious compartment. From the study it is evident that for time delay  $\tau > 5$  days, DFE is stable otherwise unstable. Numerical simulation was carried out to validate the analytic results where it was found out that  $R_0 = 0.95$  at DFE. Furthermore the results show that stability was guaranteed at EEP and is attained at  $R_0 = 1.02$ . Time delay, rate of vaccination and rate of progression from asymptomatic to infectious plays an important role in the transmission of COVID-19 and stability at DFE and EEP.

## Suggestions for Further Research

This study has not exhausted all about COVID-19 transmission dynamics. Further studies can be done on COVID-19 vaccine efficacy. The model can be extended to include co-infection between COVID-19 and TB or any other

underlying conditions. Further studies can be done on the effects of partially and fully vaccinated individuals on COVID-19 transmission dynamics.

## Disclaimer (Artificial Intelligence)

I hereby declare that NO generative AI technologies such as Large Language Models (ChatGPT, COPILOT, etc) and text-to-image generators have been used during writing or editing of this manuscript.

## Competing Interests

Authors have declared that no competing interests exist.

## References

- Aldila, D., Khoshnaw, S. H. A., Safitri, E., Anwar, Y. R., Bakry, A. R. Q., Samiadji, B. M., Anugerah, D. A., Gh, M. F. A., Ayulani, I. D., & Salim, S. N. (2020). A mathematical study on the spread of COVID-19 considering social distancing and rapid assessment: The case of Jakarta, Indonesia. *Chaos, Solitons & Fractals*, 139, 110042. <https://doi.org/10.1016/j.chaos.2020.110042>
- Algarni, A. D., Ben Hamed, A., Hamdi, M., Elmannai, H., & Meshoul, S. (2022). Mathematical COVID-19 model with vaccination: A case study in Saudi Arabia. *PeerJ Computer Science*, 8, e959. <https://doi.org/10.7717/peerj-cs.959>
- Buonomo, B., Della Marca, R., d'Onofrio, A., & Groppi, M. (2022). A behavioural modelling approach to assess the impact of COVID-19 vaccine hesitancy. *Journal of Theoretical Biology*, 534, 110973. <https://doi.org/10.1016/j.jtbi.2021.110973>
- Carpio, C. E., Sarasty, O., Hudson, D., Macharia, A., & Shibia, M. (2021). The demand for a COVID-19 vaccine in Kenya. *Human Vaccines & Immunotherapeutics*, 17(10), 3463–3471. <https://doi.org/10.1080/21645515.2021.1938494>
- Chae, S. Y., Lee, K., Lee, H. M., Jung, N., Le, Q. A., Mafwele, B. J., Lee, T. H., Kim, D. H., & Lee, J. W. (2020). Estimation of Infection Rate and Predictions of Disease Spreading Based on Initial Individuals Infected With COVID-19. *Frontiers in Physics*, 8, 311. <https://doi.org/10.3389/fphy.2020.00311>
- Diagne, M. L., Rwezaura, H., Tchoumi, S. Y., & Tchuente, J. M. (2021). A Mathematical Model of COVID-19 with Vaccination and Treatment. *Computational and Mathematical Methods in Medicine*, 2021, 1–16. <https://doi.org/10.1155/2021/1250129>
- Diekmann, O., Heesterbeek, J. A. P., & Roberts, M. G. (2010). The construction of next-generation matrices for compartmental epidemic models. *Journal of The Royal Society Interface*, 7(47), 873–885. <https://doi.org/10.1098/rsif.2009.0386>
- Lemaitre, J. C., Perez-Saez, J., Azman, A. S., Rinaldo, A., & Fellay, J. (n.d.). *Assessing the impact of non-pharmaceutical interventions on SARS-CoV-2 transmission in Switzerland*.
- Li, Q., Tang, B., Bragazzi, N. L., Xiao, Y., & Wu, J. (2020). Modeling the impact of mass influenza vaccination and public health interventions on COVID-19 epidemics with limited detection capability. *Mathematical Biosciences*, 325, 108378. <https://doi.org/10.1016/j.mbs.2020.108378>
- McCloskey, B., & Heymann, D. L. (2020). SARS to novel coronavirus – old lessons and new lessons. *Epidemiology and Infection*, 148, e22. <https://doi.org/10.1017/S0950268820000254>

- Muchiri, S. K., Muthee, R., Kiarie, H., Sitienei, J., Agweyu, A., Atkinson, P. M., Edson Utazi, C., Tatem, A. J., & Alegana, V. A. (2022). Unmet need for COVID-19 vaccination coverage in Kenya. *Vaccine*, 40(13), 2011–2019. <https://doi.org/10.1016/j.vaccine.2022.02.035>
- Musa, S. S., Tariq, A., Yuan, L., Haozhen, W., & He, D. (2022). Infection fatality rate and infection attack rate of COVID-19 in South American countries. *Infectious Diseases of Poverty*, 11(1), 40. <https://doi.org/10.1186/s40249-022-00961-5>
- Shampine, L. F., & Thompson, S. (n.d.). *Solving Delay Differential Equations with*.
- Shattock, A. J., Le Rutte, E. A., Dünner, R. P., Sen, S., Kelly, S. L., Chitnis, N., & Penny, M. A. (2022). Impact of vaccination and non-pharmaceutical interventions on SARS-CoV-2 dynamics in Switzerland. *Epidemics*, 38, 100535. <https://doi.org/10.1016/j.epidem.2021.100535>
- Shen, M., Peng, Z., Xiao, Y., & Zhang, L. (2020a). Modeling the Epidemic Trend of the 2019 Novel Coronavirus Outbreak in China. *The Innovation*, 1(3), 100048. <https://doi.org/10.1016/j.xinn.2020.100048>
- Wangari, I. M., Sewe, S., Kimathi, G., Wainaina, M., Kitetu, V., & Kaluki, W. (2021). Mathematical Modelling of COVID-19 Transmission in Kenya: A Model with Reinfection Transmission Mechanism. *Computational and Mathematical Methods in Medicine*, 2021, 1–18. <https://doi.org/10.1155/2021/5384481>
- WHO, 2020. (n.d.). *WHO REPORT Coronavirus disease 2019 (COVID-19) Situation Report – 54*. national authorities by 10 AM CET 14 March 2020.
- Xu, S., Liu, P., Mei, S., Lv, Q., Cheng, C., Lu, Y., Kong, D., Wu, X., Wen, Y., Cao, B., Gao, S., Xiong, H., Zhao, J., Huang, Y., Luo, Y., & Feng, T. (2021). Analysis of the comprehensive non-pharmaceutical interventions and measures in containing the COVID-19 epidemic in Shenzhen: A retrospective study. *BMJ Open*, 11(7), e044940. <https://doi.org/10.1136/bmjopen-2020-044940>

**Disclaimer/Publisher’s Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of the publisher and/or the editor(s). This publisher and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

© Copyright (2025): Author(s). The licensee is the journal publisher. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**Peer-review history:**

The peer review history for this paper can be accessed here (Please copy paste the total link in your browser address bar)

<https://pr.sdiarticle5.com/review-history/137911>